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Adherence to antiretroviral treatment regimens in children has been substantially researched, 
however data pertaining to adherence to prophylactic regimens in the paediatric population, 
especially infants, is not readily available. As adherence to an antiretroviral treatment 
regimen is central to ensuring that expected benefits are achieved, adherence to a 
prophylactic regimen is as important in Human Immunodeficiency Virus (HIV) prevention. 
The HPTN 046 study was a prospective cohort study conducted from June 2008 to March 
2010 in South Africa (Durban), Tanzania, Zimbabwe and Uganda. All enrolled infants 
received open label nevirapine suspension (10mg/ml) up to 6 weeks of age (day 42), at which 
point they were randomised to receive nevirapine suspension or placebo till 6 months of age. 
The dosing regimen for the first 6 weeks was as follows: 0.6ml (6mg) once daily from 3 to 7 
days after birth to 2 weeks of age, 1.5ml (15mg) once daily from 2 to5 weeks of age and 
1.8ml (18mg) once daily from 5 to 6 weeks (42 days) of age.   
Adherence to medication can be measured by various methods. The aim of this study was to 
ascertain the reliability of maternal verbal reports in measuring adherence to antiretroviral 
prophylaxis in infants in the first 6 weeks of life and evaluating the unused returned 
medication as an alternative method of measuring adherence. 
 OBJECTIVES:  
1. To measure adherence to daily use of nevirapine prophylaxis in infants at 2, 5 and 6 
weeks of age by use of maternal verbal reports. 
2. To measure adherence to daily use of nevirapine prophylaxis in infants at 2, 5 and 6 
weeks of age by assessing the volume of unused returned nevirapine suspension. 
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3. To compare the sensitivity and specificity of maternal verbal reports and unused 
returned nevirapine suspension in relation to plasma nevirapine concentration. 
4. To describe maternal and infant characteristics in association with adherence as 
measured by maternal verbal reports. 
METHODOLOGY:  
Main study: The HPTN 046 Study  
Measurement of adherence by maternal verbal reports: Enrolled participants’ mothers were 
administered a questionnaire regarding infant dosing and number of missed doses. This data 
was transferred into case report forms and captured into the main HPTN 046 database. 
Measurement of adherence by assessment of unused returned medication: Mothers of 
participants were requested by counsellors to return bottles with remaining medication from 
the previous visit at each subsequent appointment. At the 2 week, 5 week and 6 week visits, 
unused medication bottles were returned and weighed to determine adherence. The weight 
was converted to volume using the density formula (mass/volume). The dose taken was 
calculated by subtracting the returned volume from 20ml (volume of a full bottle). The 
number of missed doses was calculated from considering the expected volume that should 
have been taken and the actual volume taken.  
Substudy: The substudy was a retrospective cohort study of the HPTN 046 study.  
Measurement of adherence by plasma nevirapine level: In the substudy, plasma nevirapine 
concentrations were determined in a small sample of the substudy population for the purpose 
of comparing maternal verbal reports to weighed returned medication. Pharmacy records 
containing adherence data calculated from unused returned medication were captured and 
demographic and verbal report adherence data were extracted from the main electronic HPTN 
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046 database at 2, 5 and 6 weeks. All data were captured on a Microsoft Excel document and 
analysed using EPI-info (Version 3.4.3) and Stata (Version 12). 
RESULTS: The average adherence by maternal verbal reports and unused returned 
medication were 97.3% among 213 infants and 94.0% among 204 infants respectively. When 
evaluated against plasma NVP concentration >100ng/ml among 37 infants, the true adherence 
of maternal verbal reports and unused returned medication were 87.7% and 71.3% 
respectively. The sensitivity and specificity of maternal verbal reports against a plasma 
nevirapine concentration of ≤ 100ng/ml to detect a missed dose in the previous 3 days were 
75% and 78% (p=0.03) respectively. Overall, among infants who were classified as adherent 
by maternal verbal reports and unused returned medication, 88.4% and 87.4% of infants 
attained a nevirapine concentration above 100ng/ml respectively.  
CONCLUSION: Maternal verbal reports are a more reliable measure of adherence to infant 
antiretroviral prophylaxis in the first 6 weeks of life when compared to assessment of unused 
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DEFINITIONS AND ACRONYMS 
 
DEFINITIONS: 
Adherence: is defined as the extent to which medication is administered to participants by 
caregivers as directed by healthcare staff in the clinical research setting 
Maternal verbal reports: feedback from participants’ mothers obtained by healthcare staff in 
the clinical research setting 
Prophylaxis: is defined as medication taken to prevent disease (HIV) in the human body  
 
ACRONYMS:  
AIDS: Acquired Immune Deficiency Syndrome 
ARV: antiretroviral 
BF: Breastfeeding 
FF: Formula Feeding 
HAART: Highly Active Antiretroviral Therapy 
HIV: Human Immunodeficiency Virus 
MEMS: Medication Event Monitoring System 
PMMH: Prince Mshiyeni Memorial Hospital 
PMTCT: Prevention of mother-to-child transmission 
UNAIDS: The Joint United Nations Program on HIV and AIDS 
UNICEF: United Nations International Children's Emergency Fund 
VAS: Visual Analogue Scale 
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 Clinical trials conducted in breastfeeding populations have demonstrated that both 
intrapartum and postpartum transmission of HIV can be significantly reduced if the mother 
and/or the infant are/is receiving antiretrovirals (ARVs) (Chasela et al., 2010; Thomas et al., 
2011). Current prevention of mother-to-child transmission (PMTCT) guidelines recommend 
that HIV positive pregnant women initiate a fixed dose combination of triple antiretrovirals 
and continue until cessation of breastfeeding and nevirapine, a non-nucleoside reverse 
transcriptase inhibitor antiretroviral, be given to HIV exposed infants at birth and for 6 weeks 
thereafter as additional post-exposure prophylaxis for intrapartum and early breastfeeding 
transmission, irrespective of feeding practice or maternal ARV treatment options. (World 
Health Organisation, 2013).  
Among the estimated 1.49 million infants born to mothers infected with HIV globally, 42% 
[38-48%] received prophylactic ARVs to prevent intrapartum and postpartum HIV 
transmission in 2010 (World Health Organisation, 2011). In Sub Saharan Africa, ARV 
coverage for HIV exposed infants increased from 32% [28-36%] the previous year to 43% 
[38-48%] in 2010 (World Health Organisation, 2011).  
Antiretroviral prophylactic regimens are considered to be a powerful tool in the prevention of 
HIV (UNAIDS, 2009), however adherence to these regimens as with any other treatment 
regimen is crucial to ensure that the target of eliminating new paediatric HIV infections by 
2015 is met (World Health Organisation, 2010a).  
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Adherence in children receiving ARVs for treatment has been previously studied (Simoni et 
al., 2007), however studies reporting adherence to prophylactic medication in infants are 
lacking.  
The HPTN 046 study (Clinical Trial Registration NCT00074412) was conducted from June 
2008 to March 2010 to determine the safety and efficacy of an extended regimen of 
nevirapine in infants born to HIV-1 infected women for the prevention of vertical HIV 
transmission during breastfeeding (Coovadia, 2012). In this phase III clinical trial, adherence 
to nevirapine prophylaxis in infants was assessed by maternal verbal reports.  
In a  substudy nested in the HPTN 046 clinical trial, we evaluated two indirect measures 
(maternal verbal reports and assessment of unused returned nevirapine medication) against a 
direct measure (plasma nevirapine concentration) of adherence in these HIV exposed infants 







This literature review first aims to the give the reader a prelude to the current guidelines for 
preventing mother-to-child transmission of HIV using infant antiretroviral prophylaxis in 
HIV exposed children. Secondly, the review highlights the importance of adherence to 
antiretroviral regimens in general and describes all current methods of assessing adherence. 
More specifically, the literature review aims to highlight challenges in assessing adherence in 
children and methods commonly used and evaluated in assessing adherence in children. 
Finally, the literature review aims to report on previous studies that have assessed adherence 
to prophylactic regimens in children. The literature review was conducted using the following 
search engines: Pubmed and Google Scholar and the following search terms: adherence, 
antiretrovirals, children, paediatrics, nevirapine, prophylaxis. Due to the limited number of 
studies that have evaluated measures of adherence in children, the review was not limited to 
any specific period. 
Background 
Human Immunodeficiency Virus type 1 (HIV-1) can be passed from the mother to the baby 
during pregnancy, delivery or breastfeeding (World Health Organisation, 2014a). There is a 
35% chance that HIV will be transmitted from the infected mother to the infant in the absence 
of interventions (World Health Organisation, 2010b).  
When international PMTCT guidelines were first released by the World Health Organisation 
(WHO) in 2006, little was known about the protective effect of ARVs to prevent HIV 
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transmission from the mother to the infant during breastfeeding (World Health Organisation, 
2010b). Hence, the WHO recommended that HIV positive women who could afford, safely 
prepare and sustain formula feeding refrain from breastfeeding their infants (World Health 
Organisation, 2010c). Towards the end of 2009, as more data became available WHO then 
made a recommendation based on two major African studies (Chasela et al., 2010; The Kesho 
Bora study group, 2011) that HIV positive women who do not meet the AFASS criteria 
(Affordability, Feasibility, Acceptability, Safety and Sustainability) for formula feeding 
should exclusively breastfeed their infants for the first 6 months of life and that the mothers 
or the infants receive antiretroviral prophylaxis throughout the breastfeeding period (World 
Health Organisation, 2010c). 
Extended Breastfeeding Prophylaxis 
The first study designed to compare formula feeding to breastfeeding amongst HIV positive 
women and their HIV exposed infants who received 6 months of zidovudine prophylaxis was 
conducted in Botswana (Thior et al., 2006). In this study known as the Mashi Study, it was 
found that at the age of 7 months, HIV transmission was significantly higher in breastfed 
(BF) infants at 7 months of age (9%) compared to the formula feeding arm (FF) (5.6%). The 
formula feeding group however had a higher risk of early mortality (9.3% in FF compared to 
4.9% in BF) (Thior et al., 2006).  
In 2008, the Six week extended-dose nevirapine study (SWEN) that compared the use of a 
single dose nevirapine regimen with a six weeks course of nevirapine as extended 
prophylaxis in breastfeeding infants showed that the 6 week course of nevirapine was more 
effective in reducing perinatal HIV transmission rates at 6 weeks. This study was a combined 
analysis of data collected in Ethopia, India and Uganda. HIV exposed infants had an infection 
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rate of 2.5% (in the 6 week nevirapine group) versus 5.3% (in the single dose nevirapine 
group) at 6 weeks, however transmission rates were higher at 6 months (6.9% versus 9%) 
with both regimens (Bedri et al., 2008). 
In view of the results of the SWEN study, the design of the HPTN 046 study (Coovadia et al., 
2012) was amended to one in which all infants received 6 weeks of open label nevirapine 
suspension and thereafter randomised to receive either nevirapine or placebo till 6 months of 
age or cessation of breastfeeding (whichever came first). This study was the first to compare 
6 weeks with 6 months of nevirapine in reducing HIV transmission in breastfeeding infants. 
The study found that the overall risk of HIV transmission in infants was lower in the 6 month 
group in comparison to the 6 week group, 1.1% versus 2.4%. Among women who had a CD4 
count > 350 cells/mm3 and were not taking ARV drugs, the HIV transmission rate was 
considerably lower in the 6 month group as compared to the 6 week group, 0.7% versus 
2.8%, therefore demonstrating the importance of extended nevirapine prophylaxis (Coovadia 
et al., 2012).  
Recent evidence based PMTCT guidelines recommend that nevirapine suspension be given to 
all HIV-exposed infants at birth and for 6 weeks thereafter as post-exposure prophylaxis for 
intrapartum and very early breastfeeding transmission even if infants are formula fed or if 
women receive ARV treatment. In addition HIV exposed breastfed infants, whose mothers do 
not receive ARV treatment, should receive daily nevirapine doses until cessation of 
breastfeeding (Department of Health, 2010; 2013).  
Importance of Adherence 
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Adherence to ARVs is imperative for meeting global targets set by the WHO for reducing 
HIV incidence and HIV related deaths (World Health Organisation, 2014b). Monitoring 
adherence to both treatment and prophylactic ARV regimens is crucial while increasing 
access to ARVs. A fair amount of research pertaining to adherence to ARV treatment has 
been conducted hitherto. Adherence to ARV medication is crucial for treatment success 
(Osterberg and Blashke, 2005) which includes reduction in the risk of drug resistance and the 
achievement of virologic suppression (Mcnabb et al., 2001; Orrell et al., 2003). Poor 
adherence to antiretroviral therapy can lead to virologic failure in patients receiving ARVs 
(Ncaca, Kranzer and Orrell, 2011).  
Consequences of non-adherence to prophylactic regimens are just as critical (Mirkuzie et al., 
2011). Adherence to a PMTCT regimen undoubtedly contributes to its efficacy (Thomas et 
al., 2011) and hence adherence would be imperative in ensuring that the target of eliminating 
new paediatric HIV infections by 2015 is met (WHO, 2010a). Thus it is of the utmost 
importance that adherence to prophylactic medication is monitored to ensure expected 
benefits are achieved with newly implemented evidence-based proven ARV regimens. 
Measures of Adherence 
Direct and indirect methods are used to measure adherence (Osterberg and Blashke, 2005) in 
adults and children. Direct methods include biological assays of an active drug in the blood or 
bodily fluids and directly observed therapy (Osterberg and Blashke, 2005). Indirect methods 
can either be subjective or objective (Osterberg and Blashke, 2005). Objective measures 
include pill counts (Naar-King et al., 2005) Medication Event Monitoring Systems (MEMS) 
(Müller et al., 2008) and pharmacy refills (Osterberg and Blashke, 2005; Bagenda et al., 
2011) whilst reports by caregivers, patients and physicians are considered to be subjective 
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methods (Naar-king et al., 2005). Reported adherence can be in the form of a Visual 
Analogue Scale (VAS) which is a percentage rating system (Berg and Arnsten, 2006). 
MEMS is a system in which the medication bottle cap has a pressure sensitive microchip that 
records the date and time of each time the bottle is opened (Müller et al., 2008). The method 
of pharmacy refills involves checking the records of when prescriptions were filled especially 
if medication is obtained from one specific pharmacy or organisation (Berg and Arnsten, 
2006). Each method has its own advantages and disadvantages (Berg and Arnsten, 2006). No 
method is considered to be a gold standard in the measurement of adherence to treatment 
(Chesney, 2006). 
Studies of Antiretroviral Treatment Adherence in Children 
Adherence and different measures of adherence have been well researched in the adult 
population in both the low to middle income and high income countries (Mcnabb et al., 2001; 
Orrell et al., 2003; Mills et al., 2006; McMahon et al., 2011). However, paediatric adherence 
research is limited (Müller et al., 2008) especially research pertaining to the prophylactic use 
of ARVs. One of the few PMTCT studies that assessed adherence to prophylactic medication 
in mothers and infants in Addis Ababa focused on assessing infant adherence at birth only 
(Mirkuzie et al., 2011).  
In comparison to research conducted on adherence to prophylactic medication in infants, 
several studies have reported paediatric adherence to treatment in both the developed and 
developing countries (Simoni et al., 2007; Vreeman et al., 2008). A comprehensive review 
reported that paediatric adherence in low and middle income countries is comparable if not 
better than high income countries (Vreeman e al., 2008). Low and middle income countries 
were found to have paediatric adherence rates ranging from 49-100% (Vreeman et al., 2008). 
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Generally, paediatric adherence is far more challenging than adult adherence (Osterberg and 
Blashke, 2005). Most antiretrovirals intended for infants and children are available in oral 
granules for suspension formulation or in syrup form. These dosage formulations are often 
unpalatable (Müller et al., 2011). In comparison to adult antiretroviral therapy, administering 
medication to infants and children is quite a difficult task for caregivers as doses have to be 
measured precisely (Davies et al., 2008). An added complication to maintaining adherence to 
a regimen is that dosages of ARVs in this population are weight dependent and therefore 
constantly changing (Davies et al., 2008). Caregivers have to be devoted and persistent to 
achieve maximum paediatric adherence (Osterberg and Blashke, 2005). Several challenges 
have been associated with the administration of liquid formulations to infants (Bagenda et al., 
2011). Antiretroviral liquid formulations include nevirapine, lamivudine, zidovudine, 
abacavir, ritonavir and others. Problems with liquid formulations include altered precision 
with doses especially administered by elderly and illiterate caregivers, spillage and special 
storage requirements (Bagenda et al., 2011). It is repeatedly recommended that treatment 
support includes intensive education and training for caregivers on aspects such as method of 
dosing, amount to be dosed and timing of dosing (Müller et al., 2011).  
Infants and children have no option but to rely on caregivers to administer their medication 
(Müller et al., 2011). Moreover, caregivers usually mothers may also be infected with HIV 
and experiencing their own health and treatment challenges (Müller et al., 2011). In resource 
limited settings especially where biological parents have demised, caregivers may be the 
grandparents who are elderly and frail (Müller et al., 2011).  
Caregiver reports as a measure of paediatric adherence are heavily relied upon in clinical 
settings. However, this subjective method has previously been found to over-estimate 
adherence to ARV treatment (Müller et al., 2008; 2011; Bagenda et al., 2011). Studies 
exploring new therapeutic regimens often use the measure of plasma viral quantification 
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(HIV-1 viral load) as a marker of treatment response (Naar-king et al., 2005; Müller et al., 
2008; Burack et al., 2010; Bhattacharya and Dubey, 2011) and as an indicator for poor 
adherence. South African studies have revealed that other measures correlated with the level 
of virologic suppression whilst adherence measured by caregiver reports was overestimated 
and did not correlate with virologic suppression (Davies et al., 2008; Müller et al., 2008; 
2011). In a study by Müller, et al. (2008), ARV treatment adherence in children less than 10 
years was assessed using a caregiver self-report of missed doses by the use of VAS which is a 
rating system from 0 to 100% in steps of 10% (Müller et al., 2008). First line ARV 
combinations in this study included nevirapine suspension, although lamivudine and abacavir 
were the drugs chosen for MEMS monitoring. It was found that MEMS adherence was 
associated with virologic suppression (Müller et al., 2008). 
Two Ugandan ARV treatment studies in children, one in a rural setting and one in an urban 
setting had similar findings (Bagenda et al., 2011; Haberer et al., 2012). A retrospective study 
was conducted which included HIV infected children between 6 months and 12 years of age 
recruited from an urban setting (Bagenda et al., 2011). Adherence levels in children receiving 
liquid formulations and those receiving a fixed dose combination tablet were compared. 
Adherence was measured by pharmacy refill data, quarterly unannounced home-visit pill 
counts and caregiver self-reports in this study. Liquid formulations for infants weighing less 
than 10 kilograms included nevirapine suspension. In the urban study, caregiver self-reports 
also produced the highest estimates of adherence, confirming findings from the South African 
studies. Pharmacy refill data and home visit pill counts correlated with virologic suppression 
whereas caregiver self-reports over-estimated adherence (Bagenda et al., 2011).  
In rural south-western Uganda, an observational prospective study was conducted in which 
adherence levels and correlates of ARV adherence were reported in children between 2 and 
10 years of age (Haberer et al., 2012). Adherence was measured by caregiver report, 
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unannounced pill counts, 30 day VAS and MEMS. CD4 and viral load levels were performed 
every 6 months as standard of care and were matched with adherence data. It was found that a 
significant proportion of participants demonstrated an adherence less than 90% by MEMS 
compared to the 3 day recall caregiver report. MEMS was the only method that correlated 
with viral load which is consistent with findings by others (Müller et al., 2008; 2011; Martin 
et al., 2009). Martin, et al. (2009) compared MEMS, pill counts and interviews with patients 
and caregivers in 24 HIV infected children from around the United States. Consistent with 
other data, this study also highlighted the finding that self-reports over-estimated adherence 
(Martin et al., 2009).  
The authors of another Ugandan study also concurred with the above researchers (Nabukeera-
Barungi et al., 2007). Nabukeera-Barungi, et al. (2007) determined levels of adherence and 
factors associated with adherence in HIV infected children aged from 2 to 18 years. 
Adherence was measured by 3 day self-report by caregivers, clinic based pill counts and 
unannounced home visit pill counts. Participants taking syrups were excluded from this 
study. Home based pill counts were found to be the most reliable and no correlation was 
found between this method and the other two methods employed to measure adherence 
(Nabukeera-Barungi et al., 2007).  
Three other studies reported conflicting findings regarding the reliability of caregiver reports 
(Van Dyk et al., 2002; Naar-king et al., 2005; Weigel et al., 2009). Naar-king, et al. (2005) 
compared verbal reports and pill counts in association with concurrent plasma viral load and 
average viral load. Adherence was measured by physician reports, self-reports by children 
older than 8 years, parent reports and pill counts. . It was found that parent reports and child 
reports did not correlate with average viral load whilst physician reports did. However parent 
reports did correlate with concurrent viral load. In this study, 40% of patients did not return 
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medication to the clinic. This study found that caregiver and physician reports were more 
feasible than pill counts (Naar-king et al., 2005).  
A mixed methods study conducted in urban Lilongwe, Malawi also found caregiver reports to 
be feasible (Weigel et al., 2009).  The quantitative part of the study comprised of assessing 
children’s adherence to medication by caregiver reports and monitoring of attendance to 
clinic appointments. 47 children between the ages of 8 months and 12 years of age were 
recruited from the Lighthouse in Malawi. At each visit, caregivers were required to report 
missed doses for the previous 3 days. According to these reports, 72% of children never 
missed doses. Clinic appointment attendance was also evaluated. According to the qualitative 
component of the study, caregivers were well motivated to support children. The quantitative 
and qualitative assessments were found to complement each other (Weigel et al., 2009). 
A multicentre randomised clinical trial conducted in HIV infected children aged 4 months to 
17 years on highly active antiretroviral therapy (HAART), found that self-reports was a 
useful method of measuring adherence and that it did correlate with virologic response. 
Caregivers were administered a questionnaire every 3 months and asked about missed doses 
in the previous 3 days. For those children old enough to take medication on their own, the 
questionnaire was administered directly to them (Van Dyke et al., 2002). 
One of the objective methods of measuring adherence is the pill count. Seth, et al. (2013) 
conducted a longitudinal study in New Delhi to assess adherence to ARV therapy in HIV 
infected children younger than 15 years using the pill count method. This method was re-
assessed by a 3 day verbal recall method. Most children received a stavudine based regimen 
in the form of a fixed dose combination tablet. The required adherence level was greater than 
95%. It was found that 95.3% of children were determined to have a greater than 95% 
adherence by the pill count method and 99% by the 3 day recall method respectively. 
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Table 1: AFRICAN STUDIES 
Main 
author 
Bagenda et al. Haberer et al. Nabukeera 
Barungi et al. 
Muller et al. Muller et al. Davies et al. Wiegel at al. 
Year 
published 
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Plasma Concentrations of Antiretrovirals for Measuring Adherence 
Nevirapine suspension was selected as the antiretroviral for extended prophylaxis in infants 
the HPTN 046 study. It belongs to the class of Non-nucleoside reverse transcriptase 
inhibitors. This class of medications as well as the Protease inhibitors meet the criteria for 
therapeutic drug monitoring (TDM) (Aarnoutse et al., 2003). TDM is the measurement of 
drug concentration in the blood (Kang and Lee, 2009). Generally, TDM is useful for 
medications with a narrow therapeutic range so that medication dose can be individualised 
(Shakya et al., 2008). It has also been used to estimate patient response when a more 
intermediate measure is not adequate (Charpentier et al., 2014) or when there is large drug 
inter-individual variability (Guiard-Schmid et al., 2003). It is considered to be useful for 
medications where a relationship between plasma concentrations and antiviral efficacy exists 
(Durant et al., 2000).  
Determining plasma concentrations for ARVs is a method that has previously been utilised to 
assess adherence (Hugen et al., 2002). Plasma concentration ratio limits for HIV-Protease 
inhibitors in a reference population was determined with the goal of detecting non-adherence 
(Hugen et al., 2002). This study found that a plasma concentration outside the limits set, was 
highly indicative of non-adherence (Hugen et al., 2002). Other studies focused on other 
methods of determining pharmacokinetic parameters for ARV medications such as nevirapine 
(Veldkamp et al., 2001). Another method to estimate area under the curve (AUC) for 
nevirapine was developed (Veldkamp et al., 2001). Limited sampling strategy was studied as 
an alternate method. It was found that randomly taken samples in the 20 adult patients were 
sufficient because the decay in plasma concentrations within the dosage interval was quite 
small. This study showed that steady state 12 hourly AUC can accurately be determined 




Studies on Plasma Nevirapine Levels 
Studies in infants have previously been conducted to determine the safety and 
pharmacokinetics of nevirapine. (Mirochnick et al., 1998; Musoke et al., 1999). Mirochnick, 
et al. (1998) found that a single dose of 200mg nevirapine to the mother during labour and a 
single dose to the infant at 2mg/kg maintained serum concentrations greater than 100ng/ml 
(10 times the in vitro 50% inhibitory concentration (IC50) against HIV-1) throughout the first 
week of life (Mirochnick et al., 1998). Another study conducted in Kampala, Uganda had a 
similar finding (Musoke et al., 1999). 
 Thereafter, an open-label phase I/II study was conducted to determine the safety and trough 
concentrations of three different regimens and to determine which regimen would maintain a 
nevirapine concentration greater than 100ng/ml among breastfeeding infants for 24 weeks 
(Shetty et al., 2003). This study was conducted in antenatal clinics in Zimbabwe and South 
Africa where 106 HIV-1 infected pregnant women were enrolled. Mothers received a single 
stat dose of 200mg nevirapine and infants received nevirapine suspension within 48-72 hours 
in one of 3 dosing regimens, the once weekly (OW), twice weekly (TW) and once daily (OD) 
regimens. It was found that none of the infants had a concentration less than 100ng/ml in the 
OD arm as compared to 64% and 5 % in the OW arm and TW arms respectively. It was also 
found that neonates whose mothers received the nevirapine stat dose within 48-72 hours 
maintained nevirapine concentrations above 100ng/ml for the first week of life (Shetty et al., 
2003). 
Plasma concentrations of nevirapine have been measured in both the adult and paediatric 
populations to assess adherence (Kounfack et al., 2008; Mghamba et al., 2013). Two methods 
to assess adherence to ARV therapy were compared in the study conducted in Cameroon 
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(Kounfack et al., 2008). Self-report was compared to the objective method of drug level 
monitoring. It was found that the proportion of patients who were adherent to treatment as 
assessed by self-report was higher than that obtained by measuring plasma nevirapine 
concentration. In addition, failure to suppress viral replication (treatment failure) was 
associated with a low nevirapine concentration (<4000ng/ml) but not with self-reports. 
Adherence to ARV treatment in children (2-14 years) in Tanzania was measured by caretaker 
report, medication return and nevirapine plasma concentration (Mghamba et al., 2013). In 
agreement with the previous study, nevirapine plasma concentration was lower (85%) than 
the caretaker report (98%) and returned medication (97%). It was ascertained that nevirapine 
concentration was a good predictor of adherence as it was found to be associated with 
immunosuppression.  
Factors that affect plasma drug concentration levels (Mghamba et al., 2013) include inter-
patient variation and the timing of drawing a blood sample in relation to the last dose taken 
(Aarnoutse et al., 2003). It has previously been shown that the decay in plasma 
concentrations of nevirapine within dosage intervals is fairly small therefore randomly taken 
samples are adequate (Veldkamp et al., 2001; Smith, Dicenzo and Morse, 2001).  
Inter-individual variability may in part be explained by the variation in activity of enzymes 
involved in metabolism due to genetic polymorphisms that occur in the human body and this 
may have an effect on drug response (Clark, Brater and Johnson, 1992). It has previously 
been ascertained that nevirapine is principally metabolised by CYP3A4 and CYP2B6 when 
cytochrome P450 (CYP) reaction phenotyping of nevirapine was performed (Erickson et al., 
1999). The effect of genetic polymorphisms on nevirapine concentrations has been studied in 
both adults (Mahungu et al., 2009) and children (Saitoh et al., 2007). Previous research has 
reported that CYPB6 516 G→T polymorphism is associated with elevated nevirapine 
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concentrations in adults (Penzak et al., 2007; Mahungu et al., 2009; Schipani et al., 2011). It 
was found that homozygous mutants (TT genotype) had a decreased nevirapine clearance and 
hence a higher concentration of nevirapine in the blood plasma (Penzak et al., 2007; 
Mahungu et al., 2009; Schipani et al., 2011). Previous studies also found that nevirapine 
clearance was reduced for CYP2B6-G516T/T genotype in children (Saitoh et al., 2007; 
Swaminathan et al., 2011). In addition to the association of CYP2B6 516 with decreased 
clearance of nevirapine, the CYP2D6*17 was also associated with decreased clearance in the 
paediatric group in Malawians (Brown et al., 2012). Recent research has also been conducted 
to study the CYP2B6, CYP2A6 and UGT2B7 polymorphisms and frequencies in the African 
population in South Africa in comparison to other parts of the world (Čolić, Alessandrini and 
Pepper, 2014). Genotyping was not performed in this sub-study. 
Summary 
A summary of African studies relevant to the objectives of this substudy is tabulated in Table 
1. It has previously been demonstrated that the mother and/or the infant should take ARVs 
during the breastfeeding period to reduce HIV transmission from the mother to the infant 
(Chasela et al., 2010). Nevirapine suspension has been found to be an effective medication if 
the infant is taking ARV prophylaxis (Bedri et al., 2008). Adherence to these regimens is of 
the utmost importance in preventing transmission of HIV from the mother to the infant during 
breastfeeding. Several measures can be utilised to assess adherence to medication (Osterberg 
and Blashke, 2005). Caregiver reports have been found to over-estimate adherence (Davies et 
al., 2008; Müller et al., 2008; Bagenda et al., 2011; Haberer et al., 2012), however there are 
studies that have found these to be useful in assessing adherence in the paediatric population 
(Naar-king et al., 2005; Weigel et al., 2009). There are many challenges faced with 
administration/ handling of liquid formulations (Bagenda et al., 2011). The assessment of 
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adherence to liquids has been performed volumetrically. (Davies et al., 2008; Müller et al., 
2011; Bagenda et al., 2011). No studies have weighed nevirapine suspension for the purpose 
of assessing adherence. Although inter-patient variability may play a role in variability in 
drug concentrations, determining drug concentrations in the blood has previously been 
studied for the purpose of assessing adherence to nevirapine suspension (Kounfack et al., 
2008; Mghamba et al., 2013) and was found to correlate with viral suppression (Kounfack et 
al., 2008).  
Study Rationale  
Adherence to antiretroviral treatment regimens in children has been substantially researched 
including an evaluation of commonly used methods of assessing adherence, however data 
pertaining to adherence to prophylactic regimens in the paediatric population especially 
infants are limited. In addition, there are no studies that evaluated different methods of 
assessing adherence in this young population group receiving antiretroviral prophylaxis. As 
adherence to an antiretroviral treatment regimen is central to ensuring that expected benefits 
are achieved in children, similarly adherence to a prophylactic regimen is critical in 







Maternal verbal reports are a more reliable means of assessing adherence in children in 
comparison to weight assessments of unused returned liquid medication. 
 
AIM 
The aim of this study was to ascertain the reliability of maternal verbal reports in measuring 
adherence to antiretroviral prophylaxis in infants in the first 6 weeks of life and evaluating 
the unused returned medication as an alternative method of measuring adherence. 
 
OBJECTIVES 
1. To measure adherence to daily use of nevirapine prophylaxis in infants at 2, 5 and 6 
weeks of age by use of maternal verbal reports. 
2. To measure adherence to daily use of nevirapine prophylaxis in infants at 2, 5 and 6 
weeks of age by assessing the volume of unused returned nevirapine suspension. 
3. To compare the sensitivity and specificity of maternal verbal reports and unused 
returned nevirapine suspension in relation to plasma nevirapine concentration. 
4. To describe maternal and infant characteristics in association with adherence as 





Study Design and Main Study  
This retrospective substudy is nested within a large Phase III Clinical trial that was a 
prospective cohort study designed to investigate the safety and efficacy of extended 
nevirapine prophylaxis in HIV exposed children to prevent breastfeeding transmission of 
HIV. The HPTN 046 Phase III Clinical Trial, a double blind placebo controlled trial was 
conducted from June 2008 to March 2010 at the Umlazi Clinical Research site located on the 
grounds of the Prince Mshiyeni Memorial Hospital (PMMH) in Umlazi, South Africa and in 
Tanzania, Zimbabwe and Uganda (Coovadia et al., 2012). HIV exposed breastfed infants 
enrolled in the HPTN 046 study received open label nevirapine suspension (10mg/ml) for the 
first 6 weeks of life, and at 6 weeks eligible infants who remained HIV negative were 
randomised to receive either an extended regimen of nevirapine or placebo until 6 months of 
age or until cessation of breastfeeding, whichever was earliest. The HPTN 046 study was 
approved by the University of Kwazulu-Natal Ethics Committee (T190/03) and the 
Medicines Control Council. Mothers provided informed consent at entry into the HPTN 046 
study.  
Eligibility criteria for participation in the main study were an HIV-infected woman of 18 
years of age and older who was willing and able to provide informed consent for participation 
in the study. She was eligible if she was in her third trimester of pregnancy or on or before 
day 7 after delivery and intended to breastfeed her infant. She also needed to deliver at the 
hospital where the study facility was based and have no serious medical condition. Her infant 
was eligible for enrolment if he/she was HIV-1 DNA PCR negative on or before day 7 of life, 
a birth weight of at least 2000 grams, was able to breastfeed and born to an HIV-infected 
woman who met the eligibility criteria and had provided consent to participate. Infants were 
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excluded from enrolment into the study if their alanine aminotransferase (ALT) at birth was 
grade 2 or higher, the haemoglobin, absolute neutrophil or platelet count at birth was grade 3 
or higher, if they had a skin rash that was graded 2B (urticarial) or grade 3 and above, if there 
was suspected or confirmed clinical hepatitis or any serious illness that would hinder study 
procedures.   
Study visits in the first 6 weeks of life after enrolment (day 3-7 after birth) were scheduled 
for 2, 5 and 6 weeks. The dose at enrolment began at 0.6ml (6mg) daily until the 2 week visit 
at which point the dose increased to 1.5ml (15mg) given as a daily dose until the 5 week visit. 
At this visit, the dose was then increased to 1.8ml (18mg) daily until day 42. At each of the 
study visits mothers and infants were clinically examined, blood specimens drawn for 
laboratory investigations and storage for further research. Demographic characteristics for 
mothers and birth weight for infants were documented on case reports forms as part of the 
main study (Appendix 3). 
 
Measuring Adherence in the Main Study 
Adherence to infant prophylaxis was measured by maternal verbal reports as per study 
protocol. Adherence was also assessed by a measure of unused nevirapine suspension 
returned to the clinic at each visit. The latter was an additional site initiative to enhance the 
site’s adherence monitoring protocol. Both methods are elaborated below. 
Measurement of Adherence by maternal verbal reports: Information regarding infant 
adherence was obtained from mothers by using a structured questionnaire in the HPTN 046 
study (Coovadia et al., 2012). Questions asked at each study visit included whether infants 
missed doses since the previous visit, the number of days missed, and the reasons for missed 
doses. The mother also provided the dates of the last 3 doses before each scheduled study 
visit. Participants who missed two or more doses as reported by their mothers at each visit 
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were classified as non-adherent. Mothers also reported on whether the infants missed 2 or 
more days in a row in the period between visits (Appendix 4). 
Measurement of adherence by assessment of unused returned nevirapine:  
Nevirapine suspension is a viscous liquid that is difficult to measure volumetrically as it 
adheres to the wall of the bottle. Therefore, bottles containing suspension were weighed for 
the purpose of assessing adherence. Study medication was dispensed to mothers at each visit 
in the HPTN 046 study. Women received instructions for administration of the suspension to 
their infants. These instructions were also printed on the labels attached to the bottles of 
medication. Adherence counseling was performed after each dispensing. This was performed 
by pharmacists and re-iterated by study counselors in the mothers preferred language. The 
number of bottles dispensed varied at each visit according to the HPTN 046 protocol. Used 
bottles containing remaining nevirapine suspension were returned by mothers at the next 
visit. Each bottle was weighed independently by pharmacists. Six full bottles were weighed 
and an average was calculated to obtain a weight of 29.4g for a full bottle of nevirapine 
suspension. These bottles which contained the liquid also had the bottle piba, cap and label 
on. Each 30ml bottle contained 20ml of nevirapine suspension. The average weight of a full 
bottle of nevirapine was used to calculate the volume of remaining medication returned. The 
number of missed doses was calculated by dividing the difference between the volume used 
and volume that should have been used by the daily dosage. This figure was thereafter 
adjusted for potential spillage and adhesion of suspension to the syringe walls and tip by 
adding one dose to the measured weight of the suspension in the bottle.  
Example:  
Dispensed:  
Weight of a full bottle with piba, cap and label= 29.4g = a 




If returned weight = 15g 
Returned volume = (b x 15g)/a 
=10.2ml 
Actual dose taken: b – (returned volume) 
 = 9.8ml 
Prescribed dose: 1.8ml x 7 days = 12.6ml 
Calculation of missed doses: (12.6 – 9.8)/1.8ml 
 = 2 
 
Adherence aids were utilized to assist mothers with ensuring adherence to the infant 
prophylaxis. On the participants visit date, a calendar was generated with the use of a 
computer programme developed specifically for the HPTN 046 study. These calendars were 
unique for each participant as the medication period and appointment date differed between 
participants. These were printed and attached to the bag containing the medication. The days 
that mothers were required to dose the infant were highlighted in yellow to assist with 
medication administration. Mothers were required to cross off the date as they administered 
medication to the infant and their next appointment date was highlighted in red as a reminder 
to attend the clinic. The infant dose for that period was printed on the calendar as well as on 
the label of the bottle. Mothers were also provided with syringes marked with the specific 
dose that the infant would need to receive.  
 
Substudy Population and Methodology  
The substudy was approved by the University of Kwazulu-Natal Ethics Committee 
(BE248/13) and the HPTN 046 study team (Appendix 5). The first 225 participants were 
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included in the substudy (Figure 1). Participants were excluded from the nevirapine 
concentration substudy analyses if the study medication (nevirapine) was held as instructed 
by the study clinicians during the dosing period. 
Plasma nevirapine concentration: Nevirapine concentrations were determined in stored 
plasma samples of adequate volumes in a subgroup of participants at the 5 and 6 week visits 
for the purpose of comparing maternal verbal reports to weighed unused returned medication. 
Stored plasma samples were couriered from the Durban laboratory to the division of Clinical 
Pharmacology at the University of Cape Town. Concentrations were determined by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). The assay was validated 
according to Food and Drug Administration (FDA) and European Medicines Agency (EMA) 
guidelines. Plasma samples were extracted and chromatographic separation was achieved on 
a Luna 5 μm PFP (2), 100 A, 50 mm  2 mm analytical column. An AB Sciex API 4000 
mass spectrometer was operated at unit resolution in the multiple reaction monitoring (MRM) 
mode, monitoring the transition of the protonated molecular ions at m/z 266.9 to the product 
ions at m/z 198.2 for nevirapine, and monitoring the transition of the protonated molecular 
ions at m/z 270.1 to the product ions m/z 229.1 for the stable isotope labeled nevirapine 
internal standard. The calibration curve fitted a quadratic (weighted by 1/concentration2) 
regression over the ranges 0.0195 – 20.0µg/ml. Results from the assay were extracted and 
captured onto the excel database containing the data of the maternal verbal reports and 
unused returned nevirapine calculations.  Nevirapine concentration above 100ng/ml was used 
as a marker for adherence (10 times the in vitro IC50 against HIV) (Mirochnick et al., 1998; 
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Statistical analysis  
Categorical variables were summarized as percentages. Frequency distributions of continuous 
variables did not meet the Shapiro-Wilk W test for normal data therefore medians and inter-
quartile ranges (IQR) were used as summary measures. These variables were also 
dichotomized using commonly accepted cut-points. These variables included maternal age, 
infant birth weight, maternal CD4 count, parity, plasma nevirapine concentration and number 
of missed doses. Age was categorized into the ≤ 25 and > 25 years age groups since the 
median age was 25 in the study population. Infant birth weight was categorized as small birth 
weight (< 2.5) using the standard obstetric definition (World Health Organisation, 2004). 
Maternal and CD4 count was categorized as requiring antiretroviral treatment (CD4 ≤ 350) or 
not using the South African treatment guidelines (Department of Health, 2013). Parity was 
classified as primi or having more than one child. It was not known if having more than one 
child could hamper the mothers opportunities to administer the daily dose to her infant. A cut 
off of 100ng/ml for plasma nevirapine concentration was used to measure adherence 
(Mirochnick et al., 1998). Similarly, > 2 missed doses was used to assess adherence by verbal 
reports. Subgroups were compared using Chi Square tests or Fisher’s exact test for 
categorical variables and Odds Ratio and 95% confidence interval reported. Independent 
associations with missed dose reporting were examined using a stepwise logistic regression 
model which includes all variables.  Two sided P < 0.05 was considered statistically 










Study Population Characteristics  
A total number of 225 mother-infants pairs were included in this substudy analysis on the 
basis of availability of unused returned nevirapine data. This method was not employed 
throughout the HPTN 046 study, therefore 45% of the total number of participants did not 
have this data (Figure 1). Maternal ages ranged from 18 years to 42 years with a median age 
of 25.7 years (IQR 22.5-29.7) The majority of women (90.7%) were single and not living 
with a partner and first pregnancies were reported in one in four women. Literacy levels 
amongst the women were relatively high with 93.3% having completed at least primary 
school education. Almost half of the women (45.5%) were in an advanced stage of HIV (CD4 
≤ 350 cells/mm3) and women receiving triple ARV’s as treatment had a CD4 count of less 
than 200 cells/mm3. Two thirds of the women (64.9%) had normal vaginal deliveries and 79 
(35.1%) had caesarean sections. The mean birth weight was 3.1 (range 2-4.3) and 11.6% of 
infants (26/225) weighed under 2.5kg. 
 
Maternal Verbal Reports 
Adherence was assessed at the 2 week (n=223), 5 week (n=207) and 6 week visits (n=210). 
Three (1.3%), twelve (5.8%) and two (1.0%) women reported that 2 or more doses were 
missed at the 2, 5 and 6 week visits respectively. Adherence was calculated as 98.7% 
(220/223), 94.2% (195/207) and 99.0% (208/210) at 2, 5 and 6 week visits respectively 
(Figure 2). Average adherence for this period was then 97.3% among 213 infants. Reasons 
for missed doses amongst the 17 women that reported 2 or more missed doses included 
difficulties in drawing medication from the bottle (11.8%), misunderstanding (mothers 
stopped dosing the infant as they were not aware that they could re-use syringes provided) 
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(11.8%), mother was ill or hospitalized (17.6%), mother forgot (5.9%), missed visit (5.9%), 
mother stopped breastfeeding (29.4%), mother thought that the study medication was expired 
(5.9%), disclosure issue (5.9%) and lack of support (5.9%). Adherence in the subgroup that 
had plasma nevirapine concentrations determined at the 5 week (n=49) and 6 week visits 
(n=24) was 79.6% (39/49) and 95.8% (23/24) respectively. Average adherence for this 
subgroup was 87.7% with maternal verbal report (5 and 6 week visits). 
 
Figure 2: Adherence based on missing ≥ 2 doses: maternal verbal report (MVR), unused 
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Maternal and infant characteristics associated with Maternal Verbal Report missed 
doses at the 5 week visit 
Maternal verbal reports of 218 participants at 5 weeks were analysed. The maternal and 
infant characteristics of this group were similar to the 7 participants whose verbal reports 
were not performed (Table 2). In general, younger women who were single and were 
primigravida more often reported a missed dose than older women with a partner and who 
were multiparous, however these differences were not statistically significant. More women 
that were 25 years and younger reported a missed dose, 18% (21/116) versus 15% (15/102) 
for women above 25 years of age (OR 1.3; 95% CI 0.6-3.0). Single women were also more 
likely to report missed doses, 18% versus 5% in married/living with a partner (OR 4.1; 95% 
CI 0.5 – 31) and (OR 1.3; 95% CI 0.5 – 2.9). More women pregnant for the first time 
reported a missed dose 19% (9/48) compared to that of a multiparous woman, 16% (24/154) 
OR: 1.3 (95% CI 0.5-2.9). Women receiving an ARV regimen either received medication for 
PMTCT (1), a triple ARV regimen (2) or medication for PMTCT and a triple ARV regimen 
(3). There were also mothers that received no ARV medication (0) (Table 3). Nevirapine 
concentrations were determined in 8 infants whose mothers were on a triple ARV regimen 
containing nevirapine. The average concentration amongst these women was 1709ng/ml. The 
average concentration amongst those infants whose mothers were not exposed to nevirapine 
was 1702ng/ml hence exposure to maternal nevirapine did not alter the plasma concentrations 
in the infants. After controlling for possible confounding variables such as age, marital status, 
education, HIV clinical stage, ARV regimen and infant birth weight, a multivariate logistic 






Table 2. Sample Representation (maternal and infant characteristics) by Method 
of Adherence Assessment among the total study population (n=225) 
 
*Note: Eleven participants were placed on drug hold at 5 weeks and were included in the substudy analysis but excluded 
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Table 3. Maternal and infant characteristics in association with maternal verbal 







                               MVR MISSED DOSE    
 
  Yes (n=36)   No (n=182) 
   
 
   n (%) 
 
n (%) OR 95% CI P value 
Age        
≤ 25 years 21 (18) 
 
95 (82) 1.3 (0.6 - 3) 
 > 25 years 15 (15) 
 
87 (85) ref 
 
0.6 
Marital Status (n, %) 
      Single 35 (18) 
 
163 (82) 4.1 (0.5 – 31) 0.2 
Married 1 (5) 
 
19 (95) ref 
  Education 
      ≤ Grade 7 (Primary) 1 (7) 
 
13 (93) ref 
     > Grade 7 (Secondary) 35 (17) 
 
169 (83) 2.7 (0.3 – 21.3) 0.3 
Parity (n, %) 
      Primigravida 9 (19) 
 
39 (81) 1.3 (0.5 – 2.9) 0.6 
Multiparous 24 (16) 
 
130 (84) ref 
  HIV clinical stage and ARV       
      CD4 ≤350 (n%) 
17 (17) 81 (83) 1.1 (0.5-2.3) 0.8 
CD4 > 350 (n%) 
19 (16)  101 (84) ref   
WHO Clinical Stage (n, %)       
1 33 (16) 
 
170 (84) 1.2 (0.1 - 10) 0.9 
2 or 3 1 (14) 
 
6 (86) ref 
  Receiving ARV regimen 
(n,%) 
      0, 1 29 (18) 
 
136 (82) 1.4 (0.6 - 3.4) 0.5 
2, 3 7 (13) 
 
46 (87) ref 
  Mode of delivery (n, %) 
      Normal 25 (17) 
 
118 (83) 1.2 (0.6 – 3.0) 0.6 
C/S 11 (15) 
 
64 (85) ref 
  Birth Weight (n, %) 
      2.0 - 2.5 kg 4 (15) 
 
22 (75) ref 
  >2.5 kg 32 (17) 
 
160 (83) 1.1 1.1 (0.4 - 3) 0.9 
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Adherence based on Unused Returned Nevirapine  
The number of missed doses was calculated at the 2 week (n=225), 5 week (n=196) and 6 
week (n=191) visits. Maternal and infant characteristics did not differ between 207 
participants who were included in the analysis as compared to the 18 participants that had no 
record of returned medication (Table 2). Seven (3.1%), twenty three (11.7%) and six (3.1%) 
infants missed 2 or more than doses at the 2, 5 and 6 week visits respectively. Adherence 
based on returned nevirapine at the 2, 5 and 6 week visits was estimated as 96.9% (218/225), 
88.3% (173/196) and 96.9% (185/191) respectively (Figure 2). Average adherence for this 
period was then 94.0% among 204 infants. Adherence in the subgroup that had plasma 
nevirapine concentrations determined at the 5 week (n=49) and 6 week (n=24) visits was 
59.2% (29/49) and 83.3% (20/24) respectively. Average adherence for unused returned 
nevirapine was 71.3% for this subgroup (5 and 6 week visits).  
 
Plasma Nevirapine Concentration  
There were no distinct differences in characteristics between the 49 participants who had 
nevirapine measured and the 176 infants who were not tested for plasma nevirapine 
concentrations (Table 2). The median nevirapine concentrations were 1620 ng/ml (IQR 1000-
2220ng/ml) and 1380 ng/ml (IQR 448-2835 ng/ml) at the 5week (n=49) and 6week (n=24) 
visits respectively. 83.7% (41/49) (95%CI 70.3-92.7) and 87.5% (21/24) (95%CI 67.6-97.3) 
of the infants had a plasma nevirapine concentration of more than 100ng/ml at 5wk and 6wk 
respectively (Figure 2). Average adherence determined by nevirapine concentration was 
85.6% (5 and 6 week visits).   
 
Agreement between Plasma Nevirapine Concentration, Maternal Verbal Reports and 
Unused Returned Nevirapine in identifying missed doses  
32 
 
The sensitivity of maternal verbal report in the last 3 days and unused returned nevirapine to 
detect missed doses was exactly the same at the 5 week visit (75% [95%CI 35-97]) p = 0.9.   
The specificity is 78% [95%CI 62-89] at the 5 week visit for maternal verbal report and is 
significantly higher than nevirapine returns at this visit (42% [95%CI 26-58) (p =0.002). The 
positive predictive value is 40% (6/15) and the negative predictive value is 94% (32/34) for 
maternal verbal reports in identifying missed doses at this visit. (Table 4). The sensitivity for 
unused returned nevirapine to detect missed doses at the 6 week visit was 100% however 
there were only 3 participants in which the concentration was less than 100ng/ml. Again, the 
specificity is higher (70% [95%CI 46-88]) for the maternal verbal report than the unused 
returned nevirapine (38% [95%CI 18-62]) at the 6 week visit. 
 
Table 4. Agreement between nevirapine concentration and maternal verbal 
reports (MVR) and unused returned nevirapine (NVP) in identifying missed doses at 
the 5 week visit 
 Adherence measure Sensitivity  Specificity PPV     NPV P-value * 
 
 
      
 
 
MVR n (%) 
95%CI 
6/8 (75%)   
(35; 97)  
 32/41(78%)  
(62; 89)   
6/15 (40%) 
(16; 68)   
 32/34(94%) 
(80; 99)   
  0,03    
  Unused NVP n (%) 
95% CI 
6/8 (75%)       
(35; 97) 




 17/19 (89%)   
(67; 99) 
< 0.001    






Relationship between Maternal Verbal Reports, Unused Returned Nevirapine and 
Nevirapine Concentration in Adherent and Non-adherent participants 
At the 5 week visit, 89.7% of infants whose mothers reported adherence (missing one dose or 
not missing any doses) had a plasma nevirapine concentration of greater than 100ng/ml. The 
same percentage (89.7%) of infants that were categorised adherent as calculated from the 
unused returned nevirapine had a concentration of greater than100ng/ml. At the 6 week visit, 
87 % of infants whose mothers reported adherence had a plasma nevirapine concentration of 
greater than 100ng/ml and 85% as calculated on the unused returned nevirapine. The average 
percentage of mothers who reported that their infants were adherent and had a plasma 
concentration of above 100ng/ml was 88.4% (5 week and 6 week visits). The average 
percentage of infants categorised as adherent by unused returned nevirapine was 87.4% (5 
and 6 week visits) (Table 5). For those infants whose mothers reported missing 2 or more 
doses at the 5 week visit, 60% had a plasma nevirapine concentration of greater than 
100ng/ml. 75% of those that missed 2 or more doses according to the unused returned 
nevirapine had a plasma nevirapine concentration of greater than 100ng/ml. At the 6 week 
visit, all infants that missed 2 or more doses as per maternal verbal report and unused 











Table 5. Relationship between maternal verbal report (MVR), unused returned 
nevirapine (NVP) and NVP concentration in adherent participants (missed < 2 doses) 
Visit Infants classified as 
adherent by MVR 
n 
Infants classified as adherent 
by MVR and have > 
[100ng/ml] n (%) 
Infants classified as 
adherent by MVR and 
have < [100ng/ml] n (%) 
5 week 39 35 (89.7%) 4 (10.3%) 
6 week 23 20 (87.0%) 3 (13.0%) 
 Infants classified as 
adherent by unused NVP 
n 
Infants classified as adherent 
by unused NVP and have > 
[100ng/ml] n (%) 
Infants classified as 
adherent by unused NVP 
and have < [100ng/ml] n 
(%) 
5 week 29 26 (89.7%) 3 (10.3%) 
6 week 20 17 (85.0%) 3 (15.0%) 
 
 
Correlation between Maternal Verbal Reports and Unused Returned Nevirapine at the 
longest visit 
A comparison of the percentages during the longest period (2-5 week) reveals that there is no 
significant difference in the doses missed for nevirapine returns (21.3%) (44/207) and 
maternal verbal reports (15.5%) (32/207) (p=0.1). This indicates good agreement between the 







Other South African studies have researched adherence to ARV treatment in paediatrics 
(Davies et al., 2008; Muller et al., 2008; 2011) however studies on adherence to prophylactic 
regimens in infants have been neglected. ARV treatment studies often use viral quantification 
to explore treatment adherence since treatment failure is often associated with poor adherence 
(Naar-king et al., 2005; Müller et al., 2008; Burack et al., 2010; Bhattacharya and Dubey, 
2011). This is not possible in HIV uninfected infants, hence the success of HIV prophylactic 
regimens would be dependent on maintaining adequate drug concentrations. Unfortunately, 
measuring antiretroviral drug concentration in resource limited countries is a rare and 
privileged commodity. Hence other measures of adherence to prophylactic regimens are 
implemented. In this study adherence to antiretroviral prophylaxis in HIV exposed infants in 
the first 6 weeks of life was evaluated using two indirect methods (verbal reports and 
assessment of unused returned medication) in association with a direct method (plasma 
concentration of medication) performed in a sub-sample of infants. 
 
In summary of the findings, prophylactic adherence determined by maternal verbal reports 
exceeded 90% at all clinic visits in the 6 week period. Adherence as measured by unused 
returned medication was marginally lower at short visit intervals (enrollment-2week, 5-
6week) but significantly lower when medication was returned after a long visit interval (2-
5week) (Figure 1). The largest number of bottles containing nevirapine suspension was 
dispensed at the 2 week visit to last until the 5 week visit as per the HPTN 046 protocol and 
hence a greater number of administration issues were expected. The assessment of unused 
returned medication in adults taking tablets is generally in the form of pill counts (Davies et 
al., 2008). The volume of a liquid can be measured by the use of a measuring cylinder 
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(Davies et al., 2008; Bagenda et al., 2011; Müller et al., 2011). In this study, bottles 
containing nevirapine suspension were weighed to evaluate adherence. There are no known 
studies that have weighed nevirapine suspension to assess adherence to the prescribed 
regimen.  
 
Average adherence as reported by mothers correlated more strongly with the direct method of 
plasma nevirapine concentration in the subgroup of participants than the measure of unused 
returned nevirapine. At the 5 week visit specifically, it is apparent that adherence as per 
maternal verbal report is more similar to adherence determined by plasma nevirapine 
concentration than the measure of unused returned medication in the subgroup. It has 
previously been found that verbal reports after longer periods  are more useful than those 
after a short period (Lu et al., 2008) and may be associated with viral load suppression in 
both HIV infected children and adults (Simoni et al., 2007; Allison et al., 2010). Similarly in 
this study, the maternal verbal report correlates more strongly with the direct method than the 
measure of unused returned nevirapine at the 5 week visit which was approximately 3 weeks 
since the last visit. It was the mother’s (caregiver) responsibility to ensure good adherence in 
this study as infants assessed were between the ages of 3 days and 6 weeks of age. Mothers 
(caregivers) were also required to report on adherence. Other studies that assessed adherence 
by caregiver reports utilized 3 day recall (Van Dyk et al., 2002; Nakubeera-Barungi et al., 
2007; Davies et al., 2008; Muller et al., 2011; Mghamba et al., 2013; Seth et al., 2013) 4 day 
recall (Bhattyacharya and Dubey, 2011) and 24 hour recall methods (Naar-king et al., 2005). 
In comparison, this study required mothers to report on doses missed since the last visit 
which could have been 3 to 26 days earlier. Mothers were supplied with calendars to remind 
them to dose the infant. Although there are treatment studies that have not found caregiver 
reports to be useful (Davies et al., 2008, Müller et al., 2008, Bagenda et al., 2011), these 
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reports as well as self-reports have been found to be of value in the assessment of adherence 
in some studies (Van Dyk et al., 2002; Naar-king et al., 2005; Nieuwkerk and Oort, 2005; 
Wiegel et al., 2009; Allison et al., 2010,).  
 
Previous studies have shown that different socio-demographic or clinical characteristics may 
predict adherence to medication (Davies et al., 2008). In this study, none of the maternal or 
infant characteristics were significantly associated with mothers reporting a missed dose at 
the longest interval (2-5 week). However, there was a trend where a greater number of 
younger, single women who were primigravida reported infant missed doses (Table 1). In 
contrast, it has previously been reported that married women were more likely to be adherent 
(Ekama et al., 2012). In this study the chance of a primigravid mother reporting a missed 
dose was greater than that of a multiparous mother. In another study, it was found that in 
women taking ARVs for PMTCT, non-adherence was associated with multiparity (Kuanza et 
al., 2010). 
  
In comparison to unused returned nevirapine, maternal verbal reports correlated better with 
plasma nevirapine concentration at the longest visit (2-5 week). Although sensitivity was the 
same for both these measures at this visit, a marked difference was observed in specificity. 
The specificity for the unused returned nevirapine was significantly lower than the maternal 
verbal reports due to the unused returned nevirapine being confounded by the longer period. 
There were a number of infants that missed doses as per the measure of unused returned 
medication, but nevirapine concentration was greater than 100ng/ml (24 infants). It is 
important to bear in mind that the dose was missed at any time in the period between the 2 
week and the 5 week visit. Another reason for low specificity could be spillage. This was also 
found to be the case at the 6 week visit. It was not possible to investigate if the last few doses 
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were missed when calculating adherence using weights of unused returned nevirapine, 
whereas this information was obtained from mothers and could therefore be used in 
determining agreement between plasma nevirapine concentration and maternal verbal reports. 
For those that reported that no doses were missed (2 mothers) but the nevirapine 
concentration is less than 100ng/ml, it is possible that mothers were untruthful or inter-
individual variability played a role. The sensitivity of 75% seems low, but these figures (6/8) 
are actually quite small. 
 
Plasma drug concentration is a reflection of the last few doses that a patient has taken 
(Aarnoutse et al., 2003). Factors that affect plasma drug concentration levels (Mghamba et 
al., 2013) include inter-patient variation and the timing of drawing a blood sample in relation 
to the last dose taken (Aarnoutse et al., 2003). It has previously been shown that the decay in 
plasma concentrations of nevirapine within dosage intervals is fairly small therefore 
randomly taken samples are adequate (Veldkamp et al., 2001, Smith et al., 2001). Due to the 
fact that nevirapine has a long elimination half-life, great intra-individual variations in plasma 
concentration was not expected (Veldkamp et al., 2001, Smith, DiCenzo and Morse, 2001). 
Reaction phenotyping of nevirapine to its 4 oxidative metabolites, 2-, 3-, 8- and 12-
hydroxyNevirapine was previously performed (Erickson et al., 1999). Collective data 
demonstrated that nevirapine is metabolised primarily by cytochrome P450 CYP3A4 and 
CYP2B6 (Erickson et al., 1999). Adult studies have reported that the CYP 2B6 516G→T 
polymorphism is associated with elevated nevirapine plasma concentrations in HIV infected 
patients (Penzak et al., 2007; Mahungu et al., 2009; Schipani et al., 2011). Mahungu, et al. 
(2009) found that in addition to this polymorphism, non-Caucasian ethnicity was an 
independent predictor of nevirapine exposure. Studies conducted in infants have reported that 
those infants with the CYP2B6 516 TT (homozygous mutants) genotype had a decreased oral 
39 
 
clearance of nevirapine in comparison to those with 516GT (heterozygous) and 516 GG 
(wildtype) genotypes (Saitoh et al., 2007; Swaminathan et al., 2011). It was also found that 
60% of the study population in India were undernourished or stunted and that the main factor 
affecting nevirapine blood concentrations was age. A generic fixed dose tablet was used in 
this study and it was found that children less than 3 years of age had a 3.2 times higher risk of 
having sub-therapeutic nevirapine concentrations (Swaminathan et al., 2011). The patients in 
this sub study were not undernourished or stunted. However, they were all under 3 years of 
age. It has also previously been reported that the CYP2D6 enzymes play a role in metabolism 
in HIV infected children (Brown et al., 2012). CYP2D6*17 was associated with decreased 
clearance in Malawian children (Brown et al., 2012). It is possible that these polymorphisms 
influenced nevirapine concentrations in the infants in this study, however this was not 
assessed.  
 
It would be useful to know how many consecutive doses need to be missed for plasma 
nevirapine concentration to decrease below 100ng/ml (10 times the in vitro 50% 
concentration against HIV-1) in infants. It is not clear from previous research exactly how 
many doses can be missed consecutively in the paediatric population for the concentration to 
fall below this level. It was previously found in a study in which trough nevirapine levels 
were determined, that in order to maintain a therapeutic target of 100ng/ml in 100% of 
participants, infants had to receive a once daily dose (Shetty et al., 2003). However a twice 
weekly dose given on the first and fourth days of each week also maintained a therapeutic 
target of 100ng/ml in 62 of 65 samples (95.4%) (Shetty et al.,2003). It can be deduced from 
this study (Shetty et al., 2003) and this sub study that infants who miss two to three 
consecutive doses can still obtain the nevirapine concentration of 100ng/ml, therefore they 




Even though a dose was missed in the previous 3 days as reported by mothers in this sub-
study, as per the deduction above, it was still possible for the nevirapine concentration to be 
greater than 100ng/ml, hence the specificity of 78% for agreement between maternal verbal 
reports and nevirapine concentration in table 2. The positive predictive value of 40% (6/15) is 
the percentage of mothers that said that the infant missed one or more doses and the infant 
actually missed one or more doses. The explanation above explains the false positives and is 
the reason that there are 9 mothers that said that the infant missed one or more doses, but the 
nevirapine concentration is still above 100ng/ml. It is also important to bear in mind that 
these numbers are very small, hence the actual percentage would be low. The negative 
predictive value of 94% (32/34) is the percentage of mothers that said that their infant did not 
miss one or more doses and the infant actually did not miss one or more doses.  
 
It was also found that more infants classified as adherent (missing < 2 doses) by maternal 
verbal reports attained a nevirapine concentration above 100ng/ml in comparison to those 
classified as adherent by the measure of unused returned nevirapine in the subgroup. Even 
though the figures are similar in table 3, maternal verbal reports were more accurate. 
 
Verbal reports are often relied upon to assess adherence to medication (Bhattacharya and 
Dubey, 2010) among adults and children and this measure of adherence has been previously 
evaluated in treatment studies. Previous studies in which nevirapine concentrations were 
compared to other adherence measures including caregiver reports have shown that 
adherence to ARV treatment is an inflated figure in comparison with other measures 
(Mghamba et al., 2013). This has also found to be the case in the adult population with self-
reported adherence (Kounfack et al., 2008). There are no known evaluation studies of this 
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measure for use in assessing adherence to a prophylactic regimen in infants. Previous studies 
support the use of plasma nevirapine concentrations as a reference method in this study, as 
low nevirapine concentrations were previously associated with virologic failure in HIV 
infected adults in Cameroon (Kounfack et al., 2008; Wang et al., 2011). 
 
The direct method of determining plasma nevirapine concentrations has been used previously 
to detect non adherence (Hugen et al., 2002). In this study, it was used for the purpose of 
assessing other measures of adherence. Maternal verbal reports in this study were found to 
correlate with plasma nevirapine concentrations. Caregiver reports are utilized to a greater 
extent than other adherence measures in routine practice. It has previously been reported that 
using multiple measures of adherence is more beneficial than using a single measure (Burack 
et al., 2010). Differences between this sub study that found caregiver reports to be reliable 
and other studies that have found an over-estimation of caregiver reported adherence include 
the fact that all the caregivers in this study were biological mothers, whereas in previous 
studies, caregivers may have been other family members (Nabukeera-Barungi et al., 2007; 
Davies et al., 2008; Müller et al., 2008; 2011). In other studies, 19% (Nabukeera-Barungi et 
al., 2007), 80% (Müller et al., 2008), 75% (Müller et al., 2011) and 88% (Davies et al., 2008) 
of the caregivers were mothers, whilst in another study 42% of caregivers were either a 
biologic mother or father (Martin et al., 2009). Other caregivers in these studies were fathers, 
grandmothers, older siblings (Nabukeera-Barungi et al., 2007) and aunts (Muller et al., 2011). 
A previous study has reported that adherence in children that was reported by caregivers who 
were not biological parents was overestimated (Van Dyke et al., 2002). Another difference is 
that the infants in this study are HIV uninfected and breastfed whereas children and infants in 
other studies were all HIV infected (Nabukeera-Barungi et al., 2007; Davies et al., 2008; 
Müller et al., 2008;2011; Bagenda et al., 2011). Infants in this current study received a once 
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daily dose of the prophylactic regimen whilst other ARVs for treatment are usually a twice 
daily dose, therefore it may be easier to recall if doses were administered.  In a previous 
study, no association was found between viral outcome and caregiver reported adherence, 
however the viral load measurement was performed long after the reported adherence and 
reported adherence was only measured at one point in the year (Davies et al., 2008). In this 
sub study, caregivers (mothers) were interviewed by the study social worker at every study 
visit. In comparison, over-estimated reported adherence in another study may be attributable 
to the interview process where caregivers were interviewed by clinicians and therefore may 
not have readily disclosed missed doses (Davies et al., 2008).  The majority of monthly 
interviews conducted in another study were via telephone and not face to face (Martin et al., 
2007). It was also noted that families in this study were receiving free medication and 
evaluations hence they were more likely to inflate adherence so to avoid removal from the 
protocol (Martin et al., 2007).  Therefore, several differences can be noted between the 
current study and other studies conducted. 
 
LIMITATIONS 
A limitation of this study is that plasma nevirapine concentrations were determined in a small 
subgroup of participants. Another limitation was that the measure of unused returned 
nevirapine was confounded by the longer period when agreement was determined between 
nevirapine concentration and the unused returned medication whereas maternal verbal reports 
were for the previous 3 days. Genetic polymorphisms were not assessed, therefore the small 
group in which nevirapine concentrations were performed may have been affected by this. 
The fact that nevirapine concentrations can be maintained even after missed doses (Shetty et 





In conclusion, the maternal verbal reports are a more reliable measure of adherence to infant 
antiretroviral prophylaxis in the first 6 weeks of life in comparison to assessment of unused 
returned medication and could be useful in assessing adherence to antiretrovirals in infants 
younger than 6 weeks. It is a feasible, inexpensive method that does not possess the 




It is recommended that genetic polymorphisms should be assessed in order to exclude 
interpatient variability when resources are available to determine plasma nevirapine 


















Aarnoutse, R.E., Schapiro, J.M., Boucher, C.A.B., Hekster, Y.A and Burger, D.M., 2003. 
Therapeutic Drug Monitoring. Drugs, 63, pp. 741-753. 
 
Allison, S.M., Koenig, L.J., Marhefka, S.L., Carter, R.J., Abrams, E.J., Bulterys, M., Tepper, 
V., Palumbo, P.E., Bachanas, P.J., Farley, J.J., 2010. Assessing medication adherence of 
perinatally HIV-infected children using caregiver interviews. The Journal Association of 
Nurses in AIDS Care: JANAC, 21(6), pp. 478-488. 
 
Bagenda, A., Barlow-Mosha, L., Bagenda, D., Sakwa, R., Fowler, M.G., Musoke, P.M., 
2011. Adherence to tablet and liquid formulations of antiretroviral medication for paediatric 
HIV treatment at an urban clinic in Uganda. Annals of Tropical paediatrics, 31. pp. 235-245. 
Bedri, A., Gudetta, A.I., Kumbi, S., Lulseged, S., Mengistu, Y et al., for the Six Week 
Extended-Dose Nevirapine (SWEN) Study Team., 2006. Extended-dose nevirapine to 6 
weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and 
Uganda: an analysis of three randomized controlled trials. Lancet, 372, pp. 300-313. 
Berg, K.M and Arnsten, J.H., 2006. Practical and conceptual challenges in measuring 
antiretroviral adherence. Journal of Acquired Immune Deficiency Syndrome, 43(1), pp. S79-
S87. 
Bhattacharya, M and Dubey, A.P., 2011. Adherence to antiretroviral therapy and its 
correlates among HIV- infected children at an HIV clinic in New Delhi. Annals of Tropical 
Paediatrics, 31, pp. 331-337.  
 
Brown, K.C., Hosseinipour, M.C., Hoskins, J.M., Thirumaran, R.K., Tien, H.C., Weigel, R., 
Tausie, J., Shumba, I., Lamba, J.K., Schuetz, E.G., 2012. Exploration of CYP450 and drug 
transporter genotypes and correlations with nevirapine exposure in Malawians. 
Pharmacogenomics, 13(1), pp. 113-121. 
 
Burack, G., Gaur, S.G., Marone, R., Petrova, A., 2010. Adherence to antiretroviral therapy in 
pediatric patients with Human Immunodeficiency virus (HIV-1). Journal of pediatric 
nursing, 25, pp. 500-504. 
Charpentier, C., Eholié, S., Anglaret, X., Bertine, M., Rouzioux, C., Avettand-Fenoël, V., 
Messou, E., Minga, A., Damond, F., Plantier, J.C., Dabis, F., Peytavin, G., Brun-Vézinet, F., 
Ekouevi, D.K., 2014. Genotypic resistance profiles of HIV-2-treated patients in West Africa. 
AIDS, 28(8), pp. 1161-1169. 
 
Chasela, C., Hudgens, M., Jamieson, D., Kayira, D., Hosseinipour, M.C., Kourtis, A.P., 
Martinson, F., Tegha, G., Knight, R.J., Ahmed, Y.I., Kamwendo, D.D., Hoffman, I.F., 
Ellington, S.R., Kacheche, Z., Soko, A., Wiener, J.B., Fiscus, S.A., Kazembe, P, Mofolo, 
I.A., Chigwenembe, M., Sichali, D.S., van der Horst, C.S., 2010, Maternal or Infant 
Antiretroviral Drugs to Reduce HIV-1 Transmission. New England Journal of Medicine, 




Chesney, M.A., 2006. The elusive gold standard. Future perspectives for HIV adherence 
assessment and intervention. Journal of Acquired Immune Deficiency Syndrome, 43(1), pp. 
S149-155. 
Clark,W.G., Brater. D.C and Johnson, A.R., 1992. Goths Medical Pharmacology. Thirteenth 
edition. United States of America : Mosby-Year book Inc. 
Čolić, A., Alessandrini, M and Pepper, M.S., 2014. Pharmacogenetics of CYP2B6, CYP2A6 
and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine. 
Drug Metabolism Reviews,[e-journal], pp. 1-13. Abstract only. Available at < 
http://www.ncbi.nlm.nih.gov/pubmed/25391641> [Accessed 18 November 2014]. 
 
Coovadia, H.M., Brown, E.R., Fowler, M.G., Chipato, T., Moodley, D., Manji, K., Musoke, 
P., Stranix-Chibanda, L., Chetty, V., Fawzi, W., Nakabiito, C., Msweli, L., Kisenge, R., 
Guay, L., Mwatha, A., Lynn, D.J., Eshelman, S.H., Richardson, P., George, K., Andrew, P., 
Mofenson, L.M., Zwerski, S., Maldonado, Y., 2012. Efficacy and safety of an extended 
nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for 
prevention of postnatal HIV-1 transmission (HPTN 046): a randomized, double-blind, 
placebo-controlled trial. Lancet, 379, pp. 221-228. 
 
Davies, M.A., Boulle, A., Fakir, T., Nuttall, J., Eley, B., 2008. Adherence to antiretroviral 
therapy in young children in Cape Town, South Africa, measured by medication return and 
caregiver self-report: a prospective cohort study. BioMedCentral Pediatrics, 8, 34. 
Department of Health, 2010. The South African Antiretroviral treatment guidelines. [pdf] 




xaMergvAB&usg=AFQjCNGsSKYTGq3ctjShpcD5BY2W-BniXw> [Accessed 9 September 
2014]. 
Department of Health, 2013. The South African Antiretroviral treatment guidelines [pdf] 
South Africa : Department of Health. Available at 
<http://www.kznhealth.gov.za/medicine/2013_art_guidelines.pdf> [Accessed 4 June 2014]. 
 
Durant, J., Clevenbergh, P., Garaffo, R, Halfon, P., Icard, S., Del Giudice, P., Montagne, N., 
Schapiro, J.M and Dellamonica, P., 2000. Importance of protease inhibitor plasma levels in 
HIV-infected treated with genotypic-guided therapy:pharmacological data from the Viradapt 
study. AIDS, 14, pp. 1333-1339. 
 
Ekama, S., Herbertson, E.C., Addeh, E.J., Gab-Okafor, C.V., Onwujekwe, D.I, Tayo, F and 
Ezechi, O.C., 2012. Pattern and Determinants of Antiretroivral drug adherence among 
Nigerian pregnant women. Journal of pregnancy, article ID 851810. 
 
Erickson, D.A., Mather, G., Trager, W.F., Levy, R.H., Keirns, J.J., 1999. Characterization of 
the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by 
human hepatic cytochromes P-450. Drug Metabolism and Disposition: the biological fate of 




Guiard-Schmid, J-B., Poirier, J-M., Meynard, J-L., Bonnard, P., Gbadoe, A.H., Amiel, C., 
Calligras, F., Abraham, B., Pialoux, G., Girard, P-M., Jailon, P and Rozenbaum, W., 2003. 
High variability of plasma drug concentrations in dual protease inhibitor regimens. 
Antimicrobial agents and Chemotherapy, 47 (3), pp. 986-990. 
 
Haberer, J.E., Kiwanuka, J., Nansera, D., Ragland, K., Mellins, C., Bangsberg, D.R., 2012. 
Multiple measures reveal antiretroviral adherence successes and challenges in HIV-infected 
Ugandan children. PLoS ONE, 7(5), e36737. 
Hugen, P.W., Burger, D.M., Aarnoutse, R.E., Baede, P.A., Nieuwkerk, P.T., Koopmans, P.P., 
Hekster, Y.A., 2002. Therapeutic drug monitoring of HIV-protease inhibitors to assess 
noncompliance. Therapeutic Drug Monitoring, 24(5), pp. 579-587. 
 
Kang, J-S and Lee, M-H., 2009. Overview of therapeutic drug monitoring. The Korean 
Journal of Internal medicine, 24, pp. 1-10. 
 
Kounfack, C., Laurent, C., Peytavin, G., Ciaffi, L., Ngolle, M.D., Mawamba,Y., Essomba, C., 
Calmy, A., Mpoudi-Ngole, E., Delaporte, E., Koulla-Shiro, S., 2008. Adherence to 
antiretroviral therapy assessed by drug level monitoring and self-report in Cameroon. Journal 
of Acquired Immune Deficiency Syndromes, 48, pp. 216-219. 
 
Kuonza, L.R., Tshumsa, C.D., Shambira, G.N and Tshimanga, M., 2010. Non-adherence to 
the single dose nevirapine regimen for the prevention of mother-to-child transmission of HIV 
in Bindura town, Zimbabwe: a cross-sectional analytic study. BioMedCentral Public Health, 
10, 218. 
 
Lu, M., Safren, S.A., Skolnik, P.R., Rogers, W.H., Coady, W., Hardy, H., Wilson, I.B., 2008. 
Optimal recall period and response task for self-reported HIV medication adherence. AIDS 
and Behaviour, 12, pp. 86-94. 
Mahungu, T.W., Smith, C.J., Turner, F., Egan, D., Youle, M., Johnson, M.A., Khoo, S., 
Back, D.J and Owen, A., 2009. Cytochrome P450 2B6 516G→T is associated with plasma 
concentrations of nevirapine at both 200mg twice daily and 400mg once daily in an ethnically 
diverse population. HIV medicine, 10, pp. 310-317. 
 
Martin, S., Elliott-Desorbo, D.K., Calabrese, S., Wolters, P.L., Roby, G., Brennan, T., Wood, 
L.V., 2009. A comparison of adherence assessment methods utilised in the United States: 
perspectives of researchers, HIV-infected children and their caregivers. AIDS patient care 
and STDS, 23(8), pp. 593-601. 
McMahon, J.H., Jordan, M.R., Kelley, K., Bertagnolio, S., Hong, S.Y., Wanke, C.A., Lewin, 
S.R., Elliott, J.H., 2011. Pharmacy adherence measures to assess adherence to antiretroviral 
therapy: review of the literature and implication for treatment monitoring. HIV/AIDS, 52(4), 
pp 493-506. 
McNabb, J., Ross, J.W., Abriola, K., Turley, C., Nightingale, C.H., Nicolau, D.P., 2001. 
Adherence to Highly active antiretroviral therapy predicts virologic outcome at an inner-city 
human immunodeficiency virus clinic. HIV/AIDS, 33, pp. 700-705. 
47 
 
Mghamba, F.W., Minzi, O.M.S., Massawe, A., Sasi, P., 2013. Adherence to antiretroviral 
therapy among HIV infected children measured by caretaker report, medication return, and 
drug level in Dar Es Salaam, Tanzania. BioMedCentral Pediatrics, 13, 95.  
 
Mills, E.J., Nachega, J.B., Buchan, I., Orbinski, J., Ataran, A., Singh,S., Rachlis, B., Wu,P., 
Cooper, C., Thabane, L., Wilson, K., Guyatt, G.H., Bangsberg, D.R., 2006. Adherence to 
antiretroviral therapy in Sub-Saharan Africa and North America. Journal of the Americal 
Medical Association, 296 (6), pp. 679-690. 
Mirkuzie, A.H., Hinderaker, S.G., Sisay, M.M., Moland, K.M and Mørkve O., 2011. Current 
status of medication adherence and infant follow up in the prevention of mother to child HIV 
transmission programme in Addis Ababa: a cohort study. BioMed Central, 14, 50. 
Mirochnick, M., Fenton, T., Gagnier, P., Pav, J., Gwynne, M., Siminski, S., Sperling, R.S., 
Beckerman, K., Jimenez, E., Yogev, R., Spector, S.A., Sullivan, J.L., 1998. Pharmacokinetics 
of nevirapine in human immunodeficiency virus type 1-infected pregnant women in their 
neonates. Journal of Infectious Disease and therapy, 178, pp. 368–374. 
 
Müller, A.D., Bode, S., Myer, L., Roux, P., von Steinbüchel, N., 2008. Electronic 
measurement of adherence to pediatric antiretroviral therapy in South Africa. The Pediatric 
Infectious disease journal, 27, pp. 257-262. 
Müller, A.D., Jaspan, H.B., Myer, L., Hunter, A.L., Harling, G., Bekker,L-G., Orrell, C., 
2011. Standard measures are inadequate to monitor pediatric adherence in a resource-limited 
setting. AIDS and Behaviour, 15, pp. 422-431. 
Musoke, P., Guay, L., Bagenda, D., Mirochnick, M., Nakabiito, C., Fleming, T., Elliott, T., 
Horton, S., Dransfield, K., Pav, J.W., Murarka, A., Allen, M., Fowler, M.G., Mofenson, L., 
Hom, D., Mmiro, F., Jackson, J.B., 1999. A phase I/II study of the safety and 
pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their 
neonates (HIVNET 006). AIDS, 13, pp. 479-486. 
 
Naar-king, S., Frey, M., Harris, M., Artken, C., 2005. Measuring adherence to treatment of 
pediatric HIV/AIDS. AIDS Care, 17, pp. 345-349. 
Nabukeera-Barungi, N., Kalyesubula, I., Kekitiinwa, A., Byakika-Tusiime, J., Musoke, P., 
2007. Adherence to antiretroviral therapy in children attending Mulago Hospital, Kampala. 
Annals of Tropical paediatrics, 27, pp. 123-131. 
Ncaca, L.N., Kranzer, K and Orrell, C., 2011. Treatment interruption and variation in tablet 
taking behaviour result in viral failure: A case-control study from Cape Town, South Africa. 
PLoS ONE, 6 (8), pp. e23088. 
Nieuwkerk, P.T and Oort, F.J., 2005. Self-reported adherence to antiretroviral therapy in 
HIV-1 infection and virologic treatment response. Journal of Acquired immune Deficiency 
Syndromes, 38(4). pp. 445-448. 
 
Orrell, C., Bangsberg, D., Badri, M and Wood R., 2003. Adherence is not a barrier to 
successful antiretroviral therapy in South Africa. AIDS, 17, pp. 1369-1375. 
 
Osterberg, L and Blashke, T., 2005. Adherence to medication. New England Journal of 




Penzak, S.R., Kabuye, G., Mugyenyi, P., Mbamanya, F., Natarajan, V., Alfaro, R.M., Kityo, 
C., Formentini, E and Masur, H., 2007. Cytochrome P450 2B6 (CYP2B6) G516T influences 
nevirapine plasma concentration in HIV-infected patients in Uganda. HIV medicine, 8, pp. 
86-91. 
 
Saitoh, A., Sarles, E., Capparelli, E., Aweeka, F., Kovacs, A., Burchett, S.K., Wiznia, A., 
Nachman, S., Fenton, T and Spector, S.A., 2007. CYP2B6 genetic variants are associated 
with nevirapine pharmacokinetics and clinical response in HIV-1 infected children. AIDS, 21, 
pp. 2191-2199. 
 
Schipani, A., Wyen, C., Mahungu, T., Hendra, H., Egan, D., Siccardi, M., Davies, G., Khoo, 
S., Fätkenheuer, G., Youle, M., Rockstroh, J., Brockmeyer, N.H., Johnson, M.A., Owen, A 
and Back, D.J., 2011. Integration of population pharmacokinetics and pharmacogenetics: an 
aid to optimal nevirapine dose selection in HIV-infected individuals. The journal of 
Antimicrobial chemotherapy, 66, pp. 1332-1339. 
 
Seth, A., Gupta, R., Chandra, J., Maheshwari, A., Kumar, P and Aneja, S. 2013. Adherence 
to antiretroviral therapy and its determinants in children with HIV infection-Experience from 
Paediatric Centre of Excellence in HIV Care in North India. AIDS Care, 26, pp. 865-871. 
 
Shakya, G., Malla, S., Shakya, K.N., Shresta, R., 2008. Therapeutic Drug Monitoring of 
antileptic drugs. Journal of Nepal Medical association, 47 (71), pp. 94-97. 
 
Shetty, A.K., Coovadia, H.M., Mirochnick, M.M., Maldonado, Y., Mofenson, L.M., 
Eshelman, S.H., Fleming, T., Emel, L., George, K., Katzenstein, D.A., Wells, J., Maponga, 
C.C., Mwatha, A., Jones, S.A., Abdool Karim, S.S., Bassett, M.T., 2003. Safety and trough 
concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-
feeding infants from birth to 6 months. Journal of Acquired immune deficiency syndromes, 
34, pp. 482-90. 
 
Simoni, J.M., Montgomery, A., Martin, E., New, M., Demas, A., Rana, S., 2007. Adherence 
to Antiretroviral therapy for Pediatric HIV infection:A Qualitative systematic review with 
recommendation for research and clinical management. Pediatrics, 119 (6), pp. e1371-e1383. 
Smith, P.F., DiCenzo, R and Morse, G.D., 2001. Clinical pharmacokinetics of non-nucleoside 
reverse transcriptase inhibitors. Clinical Pharmacokinetics, 40, pp. 893-905. 
 
Swaminathan, S., Ramachandran, G., Kupparam, H.K.A., Mahalingum, V., Soundarajan, L., 
Kannabiran, B.P., Navaneethapandian, P.G.D., Shah, I., Karunaianandham, R and Sikhamani, 
R., 2011. Factors influencing plasma nevirapine levels: a study in HIV-infected children on 
generic antiretroviral treatment in India. The journal of Antimicrobial chemotherapy, 66, pp. 
1354-1359. 
 
The Kesho Bora study group., 2011. Triple antiretroviral compared with zidovudine and 
single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of 
mother-to-child transmission of HIV-1 (Kesho-Bora study): a randomised controlled trial. 
The Lancet. Infectious diseases, 11, pp. 171-179. 
Thior, I., Lockman, S., Smeaton, L.M., Shapiro, R.L., Wester, C., Heymann, S.J., Gilbert, 
P.J., Stevens, L., Peter, T., Kim, S., van Widenfelt, E., Moffat, C., Ndase, P., Arimi, P., 
49 
 
Kebaabetswe, P., Mazonde, P., Makhema, J., McIntosh, K., Novitsky, V., Lee, T-H., 
Marlink, R., Lagakos, S., Essex, M., 2006. Breastfeeding plus infant zidovudine prophylaxis 
for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child 
transmission in Botswana. Journal of the Americal medical association, 296(7), pp.794-805. 
Thomas, T.K., Masaba, R., Borkowf, C.B., Ndivo, R., Zeh, C., Misore, A., Otieno, J., 
Jamieson, D., Thigpen, M.C., Bulterys, M., Slutsker, L., De Cock, K.M., Amornkul, P.N., 
Greenberg, A.E., Fowler, M.G., 2011. Triple-Antiretroviral prophylaxis to prevent Mother-
to-child transmission through breastfeeding-The Kisumu Breastfeeding Study, Kenya: a 
clinical trial. PLoS Med, 8, e1001015. 
UNAIDS, 2009. More infants protected from HIV as access to antiretroviral drugs to prevent 
mother-to-child transmission increases. Available at 
<http://www.unaids.org/en/resources/presscentre/featurestories/2009/september/20090930wh
opmtct/> [Accessed 12 November 2012]. 
 
Van Dyke, R.B., Lee, S., Johnson, G.M., Wiznia, A., Mohan, K., Stanley, K., Morse, E.V., 
Krogstad, P.A and Nachman, S., 2002. Reported adherence as a determinant of reponse to 
highly active antiretroviral therapy in children who have human immunodeficiency virus 
infection. Pediatrics, 109(4), e61. 
 
Veldkamp, A.I., van Heeswijk, R.P., Mulder, J.W., Meenhorst, P.L., Hoetelmans, R.M.W., 
Lange, J.M.A., Beijnen, J.H., 2001. Limited sampling strategies for the estimation of the 
systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine. 
Therapeutic Drug Monitoring, 23, pp. 606-611. 
 
Vreeman, R.C., Wiehe, S.E., Pearce, E.C., Nyandiko, W.M., 2008. A systematic review of 
pediatric adherence to antiretroviral therapy in low- and middle-income countries. The 
Pediatric Infectious disease journal, 27(8). pp. 686-691. 
Wang, J., Kou, H., Fu, Q., Han, Y and Qiu,Z., 2011. Nevirapine plasma concentrations are 
associated with virologic response and hepatotoxicity in chinese patients with HIV infection. 
PLoS One, 6, e26739. 
Weigel, R., Makwiza, I., Nyirenda, J., Chiunguzeni, D., Phiri, S., Theobold, S., 2009. 
Supporting children to adhere to anti-retroviral therapy in urban Malawi: multi method 
insights. BioMedCentral Pediatrics, 9, 45. 
World Health Organisation, UNICEF, 2004. Low birthweight: country, regional and global 
estimates. [pdf] Switzerland : UNICEF and World Health Organisation. Available at 
<http://www.unicef.org/publications/files/low_birthweight_from_EY.pdf> 
[Accessed 19 February 2015]. 
 
World Health Organisation, 2010a. PMTCT strategic vision, 2010–2015 preventing mother-
to-child transmission of HIV to reach the UNGASS and millennium development goals 
moving towards the elimination of paediatric HIV. [pdf] Switzerland : World Health 
Organisation. Available at <http://www.who.int/hiv/pub/mtct/strategic_vision.pdf> 
[Accessed 15 November 2012]. 
World Health Organisation, 2010b. New guidance on prevention of mother-to-child 
transmission of HIV and infant feeding in the context of HIV. [pdf] Switzerland : World 
Health Organisation. Available at 
50 
 
<http://whqlibdoc.who.int/publications/2010/9789241599818_eng.pdf> [Accessed 9 October 
2014]. 
World Health Organisation, 2010c. Breast is always best, even for HIV positive mothers. 
Available at <http://www.who.int/bulletin/volumes/88/1/10-030110/en/> [Accessed 7 
October 2014]. 
World Health Organisation, 2011. Progress report. 2011 : Global HIV/AIDS response: 
Epidemic update and health sector progress towards universal access. [pdf] Switzerland : 
World Health Organisation. Available at 
<http://whqlibdoc.who.int/publications/2011/9789241502986_eng.pdf?ua=1> [Accessed 12 
September 2014]. 
World Health Organisation, 2013. Consolidated guidelines on the use of drugs for treating 
and preventing HIV infection: Reccomendations for a public health approach. [pdf] 
Switzerland : World Health Organisation. Available at 
<http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf> [Accessed 14 
November 2014]. 
 
World Health Organisation, 2014a. Global guidelines on criteria and processes for validation 
: Elimination of Mother-to-child transmission of HIV and Syphilis. [pdf] Switzerland : World 
Health Organisation. Available at 
<http://apps.who.int/iris/bitstream/10665/112858/1/9789241505888_eng.pdf?ua=1> 
[Accessed 14 November 2014]. 
World Health Organisation, 2014b. Millenium development goals, MDG 6: combat 
HIV/AIDS, malaria and other diseases. Available at 





















APPENDIX 1: Resubmission to journal 
APPENDIX 2: Journal feedback 
APPENDIX 3: Case Report Forms 
APPENDIX 4: Data Sheet 
APPENDIX 5: Ethics Approval letters 































































































APPENDIX 4: Data sheet 
Infant Participant ID  
 - - - 
Mother/ caregiver information: 
QUESTION 2 WEEK VISIT 5 WEEK VISIT 6 WEEK VISIT 
1. Did infant miss any doses 







              no 
 
          don’t know 
 yes 
 
              no 
 
          don’t know 
 yes 
 
              no 
 
          don’t know 
2. If number 1 is yes, were 
doses missed for 2 or more 








              no 
 
          don’t know 
 yes 
 
              no 
 
          don’t know 
 yes 
 
              no 
 
          don’t know 
 
 2 week visit 5 week visit 6 week visit 
Largest number of 
days missed 
   
 
Reasons for missed doses 2 week visit 5 week visit 6 week visit 
1. Mother/caregiver 
forgot 
   
2. Mother/caregiver was 
ill 
   
3. Family had visitors    
4. Lost bottle of study 
drug 
   
5. Family away from 
home 
   
6. Infant was ill    
7. Mother/caregiver 
thought there was side 
effects 
   
8. Other     
 
 2 week visit 5 week visit 6 week visit 
Dates of last 3 doses : 
1 
   
2    
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3    















– 2 week 
Dose that should 
have been taken – 
number of days 







Actual taken Number of 
doses missed 
         

















Dose that should 
have been taken – 
number of days 







Actual taken Number of 
doses missed 
         
















– 6 week 
Dose that should 
have been taken – 
number of days 







Actual taken Number of 
doses missed 
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Background:  Adherence to an antiretroviral regimen is imperative for treatment success in 
both HIV infected adults and children.  Likewise, adherence to antiretroviral prophylaxis is 
critical in HIV prevention.  Studies on pediatric adherence are limited, particularly the 
prophylactic use of antiretroviral drugs and treatment adherence in very young infants.  The 
HIV Prevention Trials Network (HPTN) 046 study (Clinical Trial Registration NCT00074412) 
determined the safety and efficacy of an extended regimen of nevirapine suspension in infants 
born to HIV-1 infected women for the prevention of vertical HIV transmission during 
breastfeeding.  As per protocol, adherence to nevirapine prophylaxis was measured by 
maternal verbal reports.  In addition, the pharmacy assessed the unused returned suspension.  
The aim of this sub-study was to determine the reliability of maternal verbal reports in 
measuring adherence to antiretroviral prophylaxis in infants in the first 6 weeks of life and 
evaluating the unused returned nevirapine as an alternative method of measuring adherence. 
Methods:  Maternal verbal reports and pharmacy returns indicative of “missed < 2 doses” 
were evaluated against a plasma nevirapine concentration of >100 ng/ml in a subgroup of 
infants at 2, 5 and 6 weeks of age. Plasma nevirapine concentration of >100 ng/ml was used 
as a marker of adherence (10 times the in vitro IC50 against HIV).  
Results: Adherence was 87.7% (maternal verbal report) and 71.3% (unused returned 
medication), as compared to 85.6% by plasma nevirapine concentration.  Evaluated against 
plasma nevirapine concentration <100ng/ml, the sensitivity and specificity of maternal verbal 
reports to detect a missed dose in the last 3 days were 75% and 78% (p=0.03) respectively.  
Overall, among infants who were classified as adherent based on missed doses by maternal 
verbal reports and unused returned medication, 88.4% and 87.4% of infants attained a 
nevirapine concentration above 100ng/ml respectively. 
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Conclusion:  Maternal verbal reports are a reliable measure of adherence to infant 
antiretroviral prophylaxis in the first 6 weeks of life and could be useful in assessing 
adherence to antiretroviral treatment in infants younger than 6 weeks. In the absence of 
resources or expertise to determine plasma drug concentration, we would recommend random 





















An estimated 2.3 million people were newly infected with HIV globally in 2012, of which 
260 000 were children [1].  The infection was averted in more than 670 000 children from 
2009 to 2012 due to the accessibility of services to prevent mother-to-child transmission [2] 
which includes the provision of antiretroviral (ARV) drugs that are taken by the mother 
during pregnancy and delivery and her newborn infant [3]. 
The number of women and infants that have been receiving ARV drugs for this purpose has 
been steadily increasing [4].  An estimated 88% of HIV positive pregnant women and 56% of 
HIV exposed infants received ARV prophylaxis in 2009 alone in South Africa [5].  Early 
studies have demonstrated that infant ARV prophylaxis in the first 6 weeks of life could 
significantly reduce risk of intrapartum or early breastfeeding transmission of HIV [6]. 
Consequently, evidence based prevention of mother-to-child transmission (PMTCT) 
guidelines currently recommend that nevirapine suspension must be given to all HIV-exposed 
infants at birth and for 6 weeks thereafter as post-exposure prophylaxis for intrapartum and 
early breastfeeding transmission, irrespective of feeding practice or maternal ARV treatment 
options [7-9]. 
Adherence to a PMTCT regimen undoubtedly contributes to its efficacy and hence adherence 
would be imperative to ensure that the target of eliminating new pediatric HIV infections by 
2015 is met [10,11].  Adherence is defined as the extent to which prescribed medication is 
taken by patients and is measured by direct and indirect methods [12].  Direct methods 
include biological assays of an active drug in the blood or body fluids and directly observed 
therapy (DOT).  Indirect measures include pill counts, Medication Event Monitoring System 
(MEMS), pharmacy refills and verbal reports by caregivers, patients and physicians [13-16].  
Each method has its advantages and disadvantages [17].    
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Adherence and various measures of adherence are well documented for the adult population 
in both low to middle income and high income countries [18-21].  However studies on 
pediatric adherence are limited [14] particularly the prophylactic use of ARV drugs.  
The HPTN046 prospective cohort study (Clinical Trial Registration NCT00074412) was 
conducted from June 2008 to March 2010 to determine the safety and efficacy of an extended 
regimen of nevirapine in infants born to HIV-1 infected women for the prevention of vertical 
HIV transmission during breastfeeding [8].  In this clinical trial, adherence to nevirapine 
prophylaxis in infants was assessed by maternal verbal reports.  In this sub-study we 
evaluated two indirect measures (maternal verbal reports and unused returned nevirapine 
medication) against a direct measure (plasma nevirapine concentration) of adherence in these 
HIV exposed infants receiving daily nevirapine prophylaxis for the first 6 weeks of life. The 
overall aim of this evaluation was to ascertain the reliability of maternal verbal reports and 
weight measurements of unused returned nevirapine suspension as an alternative method of 














Study design, setting and population 
This was a retrospective cohort study.  Data was retrieved from the HPTN046 study [8].  This 
study was conducted at the Umlazi Clinical Research site located on the grounds of the 
Prince Mshiyeni Memorial Hospital (PMMH) in Umlazi Township.  HIV exposed breastfed 
infants enrolled in the HPTN046 study received nevirapine suspension (10mg/ml) for the first 
6 weeks of life, and at 6 weeks eligible infants who remained HIV negative were randomized 
to receive either an extended regimen of nevirapine or placebo until 6 months of age or until 
cessation of breastfeeding, whichever was earliest.  Study visits in the first 6 weeks of life 
after enrolment (day 3-7 after birth) were scheduled for 2, 5 and 6 weeks. The dose at 
enrolment began at 0. 6ml (6mg) daily until the 2 week visit at which point the dose increased 
to 1. 5ml (15mg) given as a daily dose until the 5 week visit. At this visit, the dose was then 
increased to 1. 8ml (18mg) daily until day 42 (birth=day 0). Participants who were on study 
drug “hold” for safety evaluations were excluded from the analysis. 
The HPTN046 study was approved by the University of Kwazulu-Natal Ethics Committee 
(T190/03) and the Medicines Control Council.  Mothers provided written informed consent at 
entry into the HPTN046 study. At each visit in the main study, participants were clinically 
examined, blood specimens drawn for laboratory investigations and storage for further 
research.  This sub-study was a retrospective cohort data analysis in which data was obtained 
from the HPTN 046 study. It was approved by the University of Kwazulu-Natal Ethics 
Committee and the HPTN046 study team. 
 
Measurement of adherence by maternal verbal reports  
Information regarding infant adherence was obtained from mothers using a structured 
questionnaire.  Questions included whether infants missed doses since the previous visit, the 
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number of days missed and the reason for missed doses.  Other information obtained included 
maternal socio-demographic characteristics.  The relevant data for this sub-study were 
extracted from the main electronic database at three different time points, at the 2 week, 5 
week and 6 week visit for this study.  Participants who reported missing two or more doses 
were classified as non-adherent.  The association between demographic characteristics and 
missed doses reported by mothers was determined for the longest period (2-5 week visit).  
Mothers provided the dates of the last 3 doses given to the infant and they also reported on 
whether the infants missed 2 or more days in a row in the period between visits.  Responses 
to both questions were utilized in the assessment of adherence.   
 
Measurement of adherence by assessment of unused returned Nevirapine  
Nevirapine suspension was dispensed to mothers at each visit.  Women received instructions 
for administration of the suspension to their infants.  These instructions were also printed on 
the labels attached to the bottles of medication.  Adherence counseling was performed after 
each dispensing.  The number of bottles dispensed varied at each visit according to the 
HPTN046 protocol.  Used bottles containing remaining nevirapine suspension were returned 
by participants at the next visit.  Each bottle was weighed independently by pharmacists. Six 
full bottles were weighed and an average was calculated to obtain an average weight of 29.4g 
for a full bottle of nevirapine suspension.  The number of missed doses was calculated by 
dividing the difference between the volume used and volume that should have been used by 
the daily dosage.  This figure was thereafter adjusted for potential spillage and adhesion of 
suspension to the syringe walls and tip by adding one dose to the measured weight of the 
suspension in the bottle.   
 
Plasma Nevirapine concentration   
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Nevirapine concentrations were determined in stored plasma samples of adequate volumes in 
a subgroup of participants at the 5 and 6 week visits for the purpose of comparing maternal 
verbal reports to weighed returned medication. Concentrations were determined by LC-
MS/MS (Division of Clinical Pharmacology, University of Cape Town).  The assay was 
validated according to FDA and EMA guidelines.  Plasma samples were extracted and 
chromatographic separation was achieved on a Luna 5 μm PFP (2), 100 A, 50 mm  2 mm 
analytical column.  An AB Sciex API 4000 mass spectrometer was operated at unit resolution 
in the multiple reaction monitoring (MRM) mode, monitoring the transition of the protonated 
molecular ions at m/z 266.9 to the product ions at m/z 198.2 for Nevirapine, and monitoring 
the transition of the protonated molecular ions at m/z 270.1 to the product ions m/z 229.1 for 
the stable isotope labeled nevirapine internal standard.  The calibration curve fitted a 
quadratic (weighted by 1/concentration2) regression over the ranges 0.0195 – 20.0µg/ml.  
Nevirapine concentration above 100ng/ml was used as a marker for adherence (10 times the 
in vitro IC50 against HIV) [22,23]. 
 
Statistical analysis  
Categorical variables were summarized as percentages.  Frequency distributions of 
continuous variables did not meet the Shapiro-Wilk W test for normal data therefore medians 
and inter-quartile ranges (IQR) were used as summary measures.  These variables were also 
dichotomized using commonly accepted cut-points.  Subgroups were compared using Chi 
Square tests or Fisher’s exact test for categorical variables and Odds Ratio and 95% 
confidence interval reported.  Independent associations with missed dose reporting were 
examined using a stepwise logistic regression model which includes all variables.   Two sided 
P < 0.05 was considered statistically significant.  All analyses were performed using EPI-info 




Study population characteristics  
A total number of 225 mother-infants pairs were included in this sub-study analysis. Maternal 
ages ranged from 18 years to 42 years with a median age of 25.7 years (IQR 22.5-29.7)  The 
majority of women (90.7%) were single and not living with a partner and first pregnancies 
were reported in one in four women.  Literacy levels amongst the women were relatively high 
with 93.3% achieving grade 7.  Almost half of the women (45.5%) were in an advanced stage 
of HIV (CD4 ≤ 350 cells/mm3) and women receiving triple ARV’s as treatment had a CD4 
count of less than 200 cells/mm3[24].  Two thirds of the women (64.9%) had normal vaginal 
deliveries and 79 (35.1%) had caesarean sections.  The mean birth weight was 3.1 (range 2-
4.3) and 11.6% of infants (26/225) weighed under 2.5kg. 
 
Maternal verbal reports 
Adherence was assessed at the 2 week (n=223), 5 week (n=207) and 6 week visits (n=210).  
Three (1.3%), twelve (5.8%) and two (1.0%) women reported that 2 or more doses were 
missed at the 2, 5 and 6 week visits respectively.  Adherence was calculated as 98.7% 
(220/223), 94.2% (195/207) and 99.0% (208/210) at 2, 5 and 6 week visits respectively 
(Figure 1).  Reasons for missed doses amongst the 17 women that reported 2 or more missed 
doses included difficulties in drawing medication from the bottle (11.8%), misunderstanding 
(mothers stopped dosing the infant as they were not aware that they could re-use syringes 
provided) (11.8%), mother was ill or hospitalized (17.6%), mother forgot (5.9%), missed visit 
(5.9%), mother stopped breastfeeding (29.4%), mother thought that the study drug was 
expired (5.9%), disclosure issue (5.9%) and lack of support (5.9%).  Adherence in the 
subgroup that had plasma nevirapine concentrations determined at the 5week (n=49) and 6 
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week visits (n=24) was 79.6% (39/49) and 95.8% (23/24) respectively.  Average adherence 
for this subgroup was 87.7% with maternal verbal report (5 and 6 week visits). 
 
Maternal and infant characteristics associated with maternal verbal report missed doses 
at the 5 week visit 
In general, younger women who were single and were primigravida more often reported a 
missed dose than older women with a partner and who were multiparous however these 
differences were not statistically significant.  More women that were 25 years and younger 
reported a missed dose, 18% (21/116) versus 15% (15/102) for women above 25 years of age 
(OR 1.3; 95% CI 0.6-3.0).  Single women were also more likely to report missed doses, 18% 
versus 5% in married/living with a partner (OR 4.1; 95% CI 0.5 – 31) and (OR 1.3; 95% CI 
0.5 – 2.9).  More women pregnant for the first time reported a missed dose 19% (9/48) 
compared to that of a multiparous woman, 16% (24/154) OR: 1.3 (95% CI 0.5-2.9).  Women 
receiving an ARV regimen either received medication for PMTCT (1), a triple ARV regimen 
(2) or medication for PMTCT and a triple ARV regimen (3).  There were also mothers that 
received no ARV medication (0) (Table 1).  Nevirapine concentrations were determined in 8 
infants whose mothers were on a triple ARV regimen containing nevirapine.  The average 
concentration amongst these women was 1709ng/ml.  The average concentration amongst 
those infants whose mothers were not exposed to nevirapine was 1702ng/ml hence exposure 
to maternal nevirapine did not alter the plasma concentrations in the infants.  After 
controlling for possible confounding variables such as age, marital status, education, HIV 
clinical stage, ARV regimen and infant birth weight, a multivariate logistic regression 
showed no variables independently related to reporting of missed doses. 
 
Adherence based on unused returned Nevirapine  
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The number of missed doses was calculated at the 2 week (n=225), 5 week (n=196) and 6 
week (n=191) visits.  Seven (3.1%), twenty three (11.7%) and six (3.1%) infants missed 2 or 
more than doses at the 2, 5 and 6 week visits respectively. Adherence based on returned 
nevirapine at the 2, 5 and 6 week visits was estimated as 96.9% (218/225), 88.3% (173/196) 
and 96.9% (185/191) respectively (Figure 1).  Adherence in the subgroup that had plasma 
nevirapine concentrations determined at the 5 week (n=49) and 6 week (n=24) visits was 
59.2% (29/49) and 83.3% (20/24) respectively.  Average adherence for unused returned 
nevirapine was 71.3% for this subgroup (5 and 6 week visits).   
 
Plasma nevirapine concentration   
The median nevirapine concentrations were 1620 ng/ml (IQR 1000-2220ng/ml) and 1380 
ng/ml (IQR 448-2835 ng/ml) at the 5week (n=49) and 6week (n=24) visits respectively. 
83.7% (41/49) (95%CI 70.3-92.7) and 87.5% (21/24) (95%CI 67.6-97.3) of the infants had a 
plasma nevirapine concentration of more than 100ng/ml at 5wk and 6wk respectively (Figure 
1).  Average adherence determined by nevirapine concentration was 85.6% (5 and 6 week 
visits).     
 
Agreement between plasma nevirapine concentration, maternal verbal reports and 
unused returned nevirapine in identifying missed doses  
The sensitivity of maternal verbal report in the last 3 days and unused returned nevirapine to 
detect missed doses was exactly the same at the 5 week visit (75% [95%CI 35-97]) p = 0.9.     
The specificity was 78% [95%CI 62-89] at the 5 week visit for maternal verbal report and 
was significantly higher than nevirapine returns at this visit (42% [95%CI 26-58) (p =0.002) 
(Table 2).  The sensitivity for unused returned nevirapine to detect missed doses at the 6 
week visit was 100% however there were only 3 participants in which the concentration was 
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less than 100ng/ml.  Again, the specificity was higher (70%[95%CI 46-88]) for the maternal 
verbal report than the unused returned nevirapine (38%[95%CI 18-62]) at the 6 week visit.  
 
Relationship between maternal verbal reports, unused returned nevirapine and 
nevirapine concentration in adherent and non-adherent patients 
At the 5 week visit, 89.7% of infants whose mothers reported adherence (missing one dose or 
not missing any doses) had a plasma nevirapine concentration of greater than 100ng/ml.  The 
same percentage (89.7%) of infants that were categorized adherent as calculated from the 
unused returned nevirapine had a concentration of greater than100ng/ml.  At the 6 week visit, 
87 % of infants whose mothers reported adherence had a plasma nevirapine concentration of 
greater than 100ng/ml and 85% as calculated on the unused returned nevirapine (Table 3).   
For those infants whose mothers reported missing 2 or more doses at the 5 week visit, 60% 
had a plasma nevirapine concentration of greater than 100ng/ml.  75% of those that missed 2 
or more doses according to the unused returned nevirapine had a plasma nevirapine 
concentration of greater than 100ng/ml.  At the 6 week visit, all infants that missed 2 or more 
doses as per maternal verbal report and unused returned nevirapine had a plasma 
concentration of greater than 100ng/ml. 
 
Correlation between maternal verbal reports and unused returned nevirapine at the 
longest visit 
A comparison of the percentages during the longest period (2-5 week) reveals that there is no 
significant difference in the doses missed for nevirapine returns (21.3%) (44/207) and 
maternal verbal reports (15.5%) (32/207) (p=0.1).  This indicates good agreement between 





In this study, adherence to antiretroviral prophylaxis in HIV exposed infants in the first 6 
weeks of life was assessed using two indirect methods (verbal reports and unused returned 
medication) in association with a direct method (plasma concentration of medication).  
Prophylactic adherence determined by maternal verbal reports exceeded 90% at all clinic 
visits in the 6 week period. Adherence as measured by unused returned medication was 
marginally lower at short visit intervals but significantly lower when medication was returned 
after a long visit interval.   
Verbal reports are often relied upon to assess adherence to medication [25] among adults and 
children and this measure of adherence has been previously evaluated in treatment studies. 
There are no known evaluation studies of this measure for use in assessing adherence to a 
prophylactic regimen in children.  Previous studies have shown that adherence reported by 
caregivers is an inflated figure in comparison with other measures in HIV infected children 
[26].  This has also found to be the case in the adult population with self-reported adherence 
[27].  In our study, adherence as per maternal verbal reports was more comparable to 
adherence determined by the direct method of plasma nevirapine concentration in the 
subgroup of participants than unused returned nevirapine.  The subgroup was the small 
number of participants for who adequate volumes of plasma was available to determine 
nevirapine concentrations.  A difference can be noted in adherence based on maternal verbal 
report in the nevirapine level subgroup (79.6%) in comparison to the overall group (94.2%) at 
the 5 week visit.  This is because the subgroup included almost all (10) of the patients that 
were non-adherent in the general group (12).  Agreement between plasma nevirapine 
concentration and maternal verbal reports was found to be slightly better than the agreement 
between plasma nevirapine concentration and unused returned nevirapine at the visit after the 
longest gap.  The specificity for the unused returned nevirapine was much lower than the 
81 
 
maternal verbal reports due to the fact that the unused returned nevirapine was confounded by 
the longer period.  This was one of the limitations of the study.  It was not possible to 
investigate if the last few doses were missed when calculating adherence using weights of 
unused returned nevirapine, whereas information that mothers provided included the last 3 
doses that the infant had taken and this could therefore be used in determining agreement 
between plasma nevirapine concentration and maternal verbal reports.  This is the case 
because plasma drug concentration is a reflection of the last few doses that a patient has taken 
[28].  Factors that affect plasma drug concentration levels [26] include inter-patient variation 
and the timing of drawing a blood sample in relation to the last dose taken [28].  It has 
previously been shown that the decay in plasma concentrations of nevirapine within dosage 
intervals is fairly small therefore randomly taken samples are adequate [29,30].  Due to the 
fact that nevirapine has a long elimination half-life, great intra-individual variations in plasma 
concentration was not expected [29,30].  Nevirapine is metabolised primarily by cytochrome 
P450 CYP3A4 and CYP2B6 [31].  Adult studies have reported that the CYP 2B6 516G→T 
polymorphism is associated with elevated nevirapine plasma concentrations in HIV infected 
patients [32,33,34].  Similarly, studies conducted in infants have reported that those infants 
with the CYP2B6 516 TT (homozygous mutants) genotype had a decreased oral clearance of 
nevirapine in comparison to those with 516GT (heterozygous) and 516 GG (wildtype) 
genotypes [35,36].  It was also previously reported that the CYP2D6 enzymes play a role in 
metabolism in HIV infected children [37].  It is possible that these polymorphisms influence 
nevirapine concentrations in the infants in this study, however this was not assessed.   
It is not clear from previous research exactly how many doses can be missed consecutively in 
the pediatric population for the concentration to fall below the required level (100ng/ml -10 
times the in vitro 50% concentration against HIV-1).  It was previously found in a study 
where trough nevirapine levels were determined, that in order to maintain a therapeutic target 
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of 100ng/ml in 100% of participants, infants had to receive a once daily dose.  However a 
twice weekly dose given on the first and fourth days of each week also maintained a 
therapeutic target of 100ng/ml in 62 of 65 samples (95.4%) [38].  It can be deduced from this 
study and our sub-study that infants who miss two to three consecutive doses can still obtain 
the nevirapine concentration of 100ng/ml, therefore they would need to receive at least twice 
weekly doses given a maximum of 72 hours apart. 
In our study, the maternal verbal report had given us a better indication of adherence in 
comparison to the measure of unused returned nevirapine. It was entirely the caregiver’s 
responsibility to ensure good adherence in this study as infants assessed were between the 
ages of 3 days and 6 weeks of age.  Mothers (caregivers) were required to report adherence.  
Other studies that assessed adherence by caregiver reports utilized 3 day recall [13,26,39-41] 
4 day recall [25] and 24 hour recall methods [16].  In comparison, our study required mothers 
to also report on doses missed since the last visit which could have been 3 to 26 days earlier. 
Caregiver reports have been found to be a reliable measure in the assessment of adherence in 
some studies [16,42].   
The direct method of determining plasma nevirapine concentrations has been used previously 
to detect non adherence [43].  In our study, it was used as a gold standard, for the purpose of 
assessing other measures of adherence.  However the limitation of this study is that plasma 
nevirapine concentrations were determined in a subgroup of participants.   
Caregiver reports are utilized to a greater extent than other adherence measures in routine 
practice. It has previously been reported that using multiple measures of adherence is more 





We have concluded that maternal verbal reports are a reliable measure of adherence to infant 
antiretroviral prophylaxis in the first 6 weeks of life and could be useful in assessing 
adherence to antiretroviral treatment in infants younger than 6 weeks.  In the absence of 
resources or expertise to determine plasma drug concentration, we would recommend random 
assessments of unused returned medication. 
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TABLE 1. Maternal and infant characteristics in association with maternal verbal reports 






                                                            MVR MISSED DOSE    
 
    Yes (n=36)     No (n=182) 
   
 
      n (%) 
 
n (%) OR 95% CI P value 
Age        
≤ 25 years 21 (18) 
 
95 (82) 1.3 (0.6 - 3) 
 > 25 years 15 (15) 
 
87 (85) ref 
 
0.6 
Marital Status (n, %) 
      Single 35 (18) 
 
163 (82) 4.1 (0.5 – 31) 0.2 
Married 1 (5) 
 
19 (95) ref 
  Education 
      ≤ Grade 7 1 (7) 
 
13 (93) ref 
      > Grade 7 35 (17) 
 
169 (83) 2.7 (0.3 – 21.3) 0.3 
Parity  (n, %) 
      Primigravida 9 (19) 
 
39 (81) 1.3 (0.5 – 2.9) 0.6 
Multiparous 24 (16) 
 
130 (84) ref 
  HIV clinical stage and ARV             
      CD4 ≤350 (n%) 
17 (17) 81 (83) 1.1 (0.5-2.3) 0.8 
CD4 > 350 (n%) 
19 (16)  101 (84) ref   
WHO Clinical Stage (n, %)       
1 33 (16) 
 
170 (84) 1.2 (0.1 - 10) 0.9 
2 or 3 1 (14) 
 
6 (86) ref 
  Receiving ARV regimen 
(n,%) 
      0, 1 29 (18) 
 
136 (82) 1.4 (0.6 - 3.4) 0.5 
2, 3 7 (13) 
 
46 (87) ref 
  Mode of delivery (n, %) 
      Normal 25 (17) 
 
118 (83) 1.2 (0.6 – 3.0) 0.6 
C/S 11 (15) 
 
64 (85) ref 
  Birth Weight (n, %) 
      2.0 - 2.5 kg 4 (15) 
 
22 (75) ref 
  >2.5 kg 32 (17) 
 
160 (83) 1.1 1.1 (0.4 - 3) 0.9 
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TABLE 2. Agreement between nevirapine concentration and maternal verbal reports 
(MVR) and unused returned nevirapine (NVP) in identifying missed doses at the 5 week visit 
 Adherence measure Sensitivity  Specificity PPV  NPV P-value * 
 
 
       
 
 
MVR n (%) 
95%CI 
6/8 (75%)      
(35; 97)   
 32/41 (78%)    
(62; 89)    
6/15 (40%) 
(16; 68)    
 32/34 (94%) 
(80; 99)    
   0,03    
  unused returned NVP n (%) 
95% CI 
6/8 (75%)            
(35; 97) 
 17/41 (42%)    
(26; 58) 
6/30 (20%)  
(8; 39) 
 17/19 (89%)    
(67; 99) 
< 0.001    





TABLE 3. Relationship between maternal verbal report (MVR), unused returned 
nevirapine (NVP) and NVP concentration in adherent patients (missed < 2 doses) 
Visit Infants classified as 
adherent by MVR(n) 
Infants classified as adherent 
by MVR and have > 
[100ng/ml] n(%) 
Infants classified as 
adherent by MVR and have 
< [100ng/ml] n(%) 
5 week 39 35 (89.7%) 4 (10.3%) 
6 week 23 20 (87.0%) 3 (13.0%) 
 Infants classified as 
adherent by unused 
NVP(n) 
Infants classified as adherent 
by unused NVP and have > 
[100ng/ml] n(%) 
Infants classified as 
adherent by unused NVP 
and have < [100ng/ml] 
n(%) 
5 week 29 26 (89.7%) 3 (10.3%) 










Detailed Legend  
Figure 1 Adherence based on missing ≥2 doses: Maternal verbal report (MVR), Unused 
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